



The biology of ergothioneine, an antioxidant nutraceutical

Irina Borodina¹, Louise C. Kenny², Cathal M. McCarthy^{3,4}, Kalaivani Paramasivan¹, Etheresia Pretorius⁵, Timothy J. Roberts^{5,6}, Steven A. van der Hoek¹ and Douglas B. Kell^{1,5,6*} 

¹*The Novo Nordisk Foundation Center for Biosustainability, Building 220, Chemitorvet 200, Technical University of Denmark, 2800 Kongens Lyngby, Denmark*

²*Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool L8 7SS, UK*

³*Irish Centre for Fetal and Neonatal Translational Research (INFANT), Cork University Maternity Hospital, Cork, Republic of Ireland*

⁴*Department of Pharmacology and Therapeutics, Western Gateway Building, University College Cork, Cork, Republic of Ireland*

⁵*Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1 Matieland, 7602, South Africa*

⁶*Department of Biochemistry, Institute of Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown Street, Liverpool L69 7ZB, UK*

Abstract

Ergothioneine (ERG) is an unusual thio-histidine betaine amino acid that has potent antioxidant activities. It is synthesised by a variety of microbes, especially fungi (including in mushroom fruiting bodies) and actinobacteria, but is not synthesised by plants and animals who acquire it via the soil and their diet, respectively. Animals have evolved a highly selective transporter for it, known as solute carrier family 22, member 4 (SLC22A4) in humans, signifying its importance, and ERG may even have the status of a vitamin. ERG accumulates differentially in various tissues, according to their expression of SLC22A4, favouring those such as erythrocytes that may be subject to oxidative stress. Mushroom or ERG consumption seems to provide significant prevention against oxidative stress in a large variety of systems. ERG seems to have strong cytoprotective status, and its concentration is lowered in a number of chronic inflammatory diseases. It has been passed as safe by regulatory agencies, and may have value as a nutraceutical and antioxidant more generally.

Key words: Ergothioneine: SLC22A4: Oxidative stress: Cytoprotectants: Nutraceuticals

(Received 1 July 2019; revised 20 November 2019; accepted 25 November 2019)

Introduction

Most of the classical vitamins such as vitamins A, B₁, B₂, B₃, C, D, etc., were discovered by means of the fact that an inadequacy in their supply led to overt forms of deficiency disease such as blindness, beri-beri, pellagra, scurvy, rickets and so on. Consequently, it was easy to establish those food sources that contained such vitamins, since they relieved or prevented the relevant syndromes^(1,2). It is correspondingly hard, by these means, to detect the presence of a vitamin if it is present in virtually every foodstuff that an individual consumes. Recently, however, 1-(+)-ergothioneine, hereafter ergothioneine (ERG), has emerged^(3–10) as an important nutrient, and indeed possible vitamin⁽³⁾, that has precisely these properties of a very widespread occurrence coupled, commonly, to a functional undersupply.

A related class of nutrient, which has not been demonstrated as necessary or essential for life yet provides health benefits

when added at levels greater than a normal diet generally provides, has come to be known as nutraceuticals, a coinage based on an amalgamation of 'nutrition' and 'pharmaceutical'⁽¹¹⁾. Interest in such nutraceuticals, also known as 'functional foods', has increased enormously over the last few decades^(11–22) as our understanding of the important roles of diet in health has improved. However, the enthusiasm for such products has not always been matched by the extent or quality of the evidence for their efficacy^(20,23–28).

Since ERG classes as a nutraceutical, it seems timely to bring together the extensive but widespread knowledge of its biology so that it may be made more widely available, and that is the purpose of this review.

Discovery and structure

ERG is a somewhat unusual betaine amino acid. It was discovered by Charles Tanret in 1909 while investigating the ergot

Abbreviations: egt, early G1 transcript; ERG, ergothioneine; O₂^{•-}, oxygen radical; OH[•], hydroxyl radical; SLC22A4, solute carrier family 22, member 4.

* **Corresponding author:** Douglas B. Kell, email dbk@liv.ac.uk






Fig. 1. Structures of ergothioneine and related molecules. For a colour figure, see the online version of the paper.

fungus *Claviceps purpurea*^(29,30). It is also known as 2-mercapto-histidine trimethylbetaine, and its formal International Union of Pure and Applied Chemistry (IUPAC) name is (2*S*)-3-(2-thioxo-2,3-dihydro-1*H*-imidazol-4-yl)-2-(trimethylammonio)propanoate. It is an *L*-histidine derivative that is $N^{\alpha},N^{\alpha},N^{\alpha}$ -trimethyl-*L*-histidine in which the hydrogen at position 2 on the imidazole ring is replaced by a mercapto group. Its structure⁽³¹⁾, and those of some related molecules, is given in Fig. 1, indicating that is a tautomer that has both a thiol and a thione form. Although it is a thiol, and hence an antioxidant^(32,33), the thione tautomer is predominant at physiological pH^(34,35), and this makes it unusually resistant to autoxidation, i.e. simple oxidation by molecular O_2 ^(32,36–38). Its midpoint potential for a thiol is consequently unusually high, being +0.06 V *v.* –0.2 to –0.4 V for typical thiols including glutathione^(4,39–41) and mycothiol^(42,43), and –0.193 V for the also somewhat oxidising thiol cofactor coenzyme M, which is 2-mercaptoethanesulfonate⁽⁴⁴⁾. Its reaction with hydroxyl radicals (OH^{\bullet}) is virtually instantaneous, while it reacts only more slowly with H_2O_2 and/or $O_2^{\bullet-}$ ⁽³⁸⁾. Its Se equivalent is known as selenoneine and also has strong antioxidant properties^(45–52), but is not otherwise discussed here.

From a pharmaco-chemical point of view ERG is also unusual, since – using our standard substructure analysis^(53,54) in KNIME⁽⁵⁵⁾ – we note that just two drugs marketed for human consumption (the anti-thyroxine-production drug methimazole and its pro-drug carbimazole, Fig. 1), and no endogenous genome-encoded metabolites from Recon2⁽⁵⁶⁾ contain the imidazole-2-thione substructure⁽⁵⁷⁾. This said, a good many fungicides do contain the benzimidazole substructure⁽⁵⁸⁾, and a variety of benzothiazoles are used as dyes.

Biosynthesis and phylogenetic distribution

A particular feature of ERG is that although it is more or less universally distributed among higher organisms, none of them – as

is consistent with the idea that it may in fact be a vitamin requiring exogenous sources – can in fact biosynthesise it. The chief organisms capable of its synthesis are fungi and certain yeasts^(59,60), though actinobacteria and certain other micro-organisms^(60–66), including the slime mould *Physarum polycephalum*⁽⁶⁵⁾, cyanobacteria^(67–71) and methylotrophs⁽⁷²⁾ are also naturally capable of its production. The related mycothiol is typically ten times more concentrated in actinobacteria than is ERG⁽⁷³⁾, and its biosynthetic pathway might provide an antitubercular drug target. Other organisms acquire ERG through transporter-mediated uptake. Thus higher plants contain it but do not biosynthesise it⁽⁷⁴⁾; instead they and other organisms^(68,75) take it up from fungal production in the soil^(76–79), and possibly via actinobacterial⁽⁸⁰⁾ or fungal^(80,81) symbionts. Animals are also considered not to biosynthesise it^(82,83), and accumulate it using a particular transporter, detailed below, via the plants and animals that they eat. Although not easy, it is possible to raise animals such as pigs on a diet such as casein, sucrose, lard, butter and salts that is considered to lack ERG; such animals are said to have undetectable levels of the compound⁽⁸⁴⁾, and rats treated similarly have reproduced^(85,86). However, we do not know the minimum amount and its location that animals need, and these are old experiments that need to be repeated with modern techniques with lower detection limits. Only then might we have a definitive statement as to whether ERG is absolutely required as a true vitamin or not, and if so in what amounts for health. In a similar vein, ERG can be present in cell culture media and cells with organic cation transporter N1 (OCTN1)/solute carrier family 22, member 4 (SLC22A4) can accumulate it⁽⁸⁷⁾, a fact little considered to date in cell culture studies.

To the extent that ERG is a ‘secondary’ metabolite, defined⁽⁸⁸⁾ as a molecule whose synthesis has a relatively restricted distribution in different organisms, the biosynthetic pathways diverge from primary metabolism via the amino acids histidine, cysteine and methionine^(89–94). Thus (Fig. 2), histidine is trimethylated




Fig. 2. The two main pathways of aerobic ergothioneine (ERG) biosynthesis, noting the relevant enzymes and thumbnails of three-dimensional structures where known. SAM, S-adenosyl methionine. For a colour figure, see the online version of the paper.

Table 1. Biosynthesis of ergothioneine in various non-recombinant micro-organisms

Organism	Selected references
<i>Aspergillus fumigatus</i>	(257)
<i>Aspergillus niger</i>	(59)
<i>Aureobasidium pullulans</i>	(113)
<i>Burkholderia pseudomallei</i>	(565)
<i>Chlorobium limicola</i>	(99,100)
<i>Claviceps purpurea</i>	(105,566,567)
<i>Lactobacillus casei</i>	(568)
<i>Methylobacterium aquaticum</i>	(72)
<i>Mycobacterium tuberculosis</i>	(91–93)
<i>Neurospora crassa</i>	(89)
<i>Schizosaccharomyces pombe</i>	(50,569)
<i>Streptomyces coelicolor</i>	(255)

using S-adenosyl methionine to form trimethyl histidine, also known as hercynine^(95,96). This reacts oxidatively with cysteine to form hercynylcysteine sulfoxide⁽⁹⁷⁾, which is converted to ERG. In some organisms, hercynine takes a more convoluted route via γ -glutamylhercynylcysteine sulfoxide (Fig. 2)⁽⁹⁴⁾. Table 1 provides references for different organisms. An excellent phylogenetic analysis is given by Jones *et al.*⁽⁶⁰⁾. In more recent work, it has been suggested that ERG was probably first biosynthesised by anaerobes using a slightly different route that converts hercynine directly to ERG^(98–100), and that was later repurposed.

Three-dimensional structures are known for a number of the relevant enzymes, including mycobacterial EgtB⁽¹⁰¹⁾ for example, PDB 4XBE, EgtC⁽¹⁰²⁾ for example, PDB 4ZFI, EgtD^(103–105) for example, PDB 4PIM, and *Neurospora crassa* early G1 transcript 2 (egt2) which is like egtE⁽¹⁰⁶⁾ for example, PDB 5UTS.

Very recently, EgtB from *Candidatus Chloracidobacterium thermophilum* was crystallised⁽¹⁰⁷⁾, and engineered towards Egt1 activity. Thumbnails are given in Fig. 2. Egt1 from *N. crassa* is 876 amino acids long⁽¹⁰⁸⁾, while egtD (from *Mycobacterium tuberculosis*⁽¹⁰⁹⁾) is just 321 amino acids long; since the N-terminal sequences are well conserved (Fig. 3), this implies an extra C-terminal domain catalysing the production of hercynylcysteine sulfoxide from hercynine.

In addition, enantiopure L-ERG has been synthesised chemically^(76,110–112), and by fermentation of genetically engineered micro-organisms (Table 2). Initial efforts in ERG synthesis were carried out in *Schizosaccharomyces pombe* using *egt1* overexpression under an inducible promoter. The N starvation and glucose starvation conditions causing long quiescence led to the maximum ERG production of 1606.3 μM while the wild-type strain produced 0.3 μM ⁽⁵⁰⁾. *Methylobacterium aquaticum* strain 22A was engineered by expressing an additional copy of *egtBD* genes and by deleting the gene encoding histidine ammonia lyase, which degrades an ERG precursor L-histidine. The resulting strain produced up to 7.0 mg EGT/g dry cell weight and 100 μg EGT/5 ml per 7 d in test-tubes⁽¹¹³⁾. The filamentous fungus *Aspergillus oryzae* has also been engineered to produce ERG by expression of *egt1* and *egt2* genes from *N. crassa*, resulting in 231 mg ERG per kg of solid media⁽¹¹⁴⁾.

Expression of *egtBCDE* genes from *Mycobacterium smegmatis* in *Escherichia coli* and optimisation of medium composition has led to 24 mg/l or 104 μM of secreted ERG⁽¹¹⁵⁾. The *egtA* gene from *M. smegmatis* was not expressed because *E. coli* contains a homologous glutamate–cysteine ligase encoded by *gsbA* and involved in glutathione biosynthesis.

S. cerevisiae has a generally recognised as safe (GRAS) status and has been exploited for the commercial production of several nutraceutical compounds⁽¹¹⁸⁾; it is thus a highly attractive host for the production of ERG. We have tested sixteen different pathway variants, nine containing only fungal genes, one with bacterial genes from *M. smegmatis*, and six hybrid pathway variants containing both fungal and bacterial transgenes. The best-performing strain contained *egt1* from *N. crassa* and *egt2* from *C. purpurea*. The composition of the medium was improved using a fractional factorial design. Fed-batch cultivation resulted in 598 (SD 18) mg/l ERG after an 84-h fermentation. Some 60 % of the measured ERG was extracellular and the rest accumulated in the cells. Table 2 summarises the various recombinant expression hosts that have been used.

The distribution of solute transporters between tissues in differentiated organisms is particularly heterogeneous⁽¹¹⁹⁾, and it is to be expected that both SLC22A4 and ERG might also be distributed heterogeneously as well. This is indeed the case, their distribution being especially high in tissues that are considered to have the potential for oxidative stress⁽⁴⁾, such as erythrocytes^(120–129), bone marrow⁽¹³⁰⁾, liver and kidney^(85,131), seminal fluid^(132,133) and the lens and cornea of the eyes⁽¹³⁴⁾. It may also be accumulated in the CNS^(135,136).

Finally, here, we note – as with the activity of the ‘master Fe regulator’ hepcidin^(137–141), that acts chiefly via the ferrous Fe transporter ferroportin – that the action of a transporter in concentrating a substance in one tissue will typically lead to its depletion from another. Consequently, it is necessary to measure all relevant compartments to assess whether a molecule such as ERG, whose distribution is strictly transporter-mediated, is protective against a particular disease/effect or otherwise in a particular place or case.

SLC22A4: the ergothioneine transporter

Although this view remains controversial, even hydrophobic molecules do not normally ‘float across’ whatever phospholipid bilayer portion of cells may be untrammelled by proteins. Xenobiotics in particular need to ‘hitchhike’ on protein transporters that have presumably evolved for ‘natural’ substrates but that are capable of their uptake^(142–152). While transporters seem to have remained somewhat understudied⁽¹⁵³⁾, those transporters involved in uptake and encoded by the human genome are now catalogued formally as SLC for solute carriers^(154,155), with efflux transporters mainly being classed as ABC families⁽¹⁵⁶⁾.

One solute carrier, previously known as organic cation transporter N1 (OCTN1)^(157,158), and now known as SLC22A4 (the human version is Uniprot Q9H015), a 551-amino-acid transporter with three glycosylation sites, is of special interest. It had been designated as a transporter of carnitine and of the (non-physiological) tetraethylammonium cation. However, in a really groundbreaking paper, Gründemann *et al.*⁽¹³⁰⁾ recognised that the rates observed (using radioisotopes) were too small to be physiologically meaningful, and using a method that we would now refer to as ‘untargeted metabolomics’^(159–164), they incubated two kinds of HEK293 cells in serum. The first were normal cells, that, as with many transporters⁽¹¹⁹⁾, do not

in fact express SLC22A4 at significant levels, while the second had been engineered to overexpress the transporter. They then simply looked for those molecules that were most differentially taken up, a molecule called stachydrine, also known as proline betaine, being the main one observed. Stachydrine is a constituent of citrus juices^(165–167). Some elementary cheminformatics based on structure similarity searches^(57,168) indicated that ERG, as a betaine, was indeed similar to stachydrine. Incubating the cells just with ERG showed that it was taken up about 100 times more quickly than was tetraethylammonium, leading to the designation of SLC22A4 as ‘the’ ERG transporter⁽¹³⁰⁾. Subsequent work^(87,169–172) has confirmed and reinforced this view of SLC22A4 and its homologues⁽¹⁷³⁾ as having significant specificity for ERG, and weak activity for various drugs^(174–177). It is concentrative, coupled in humans to influx of 2 or 3 Na⁺ ions per ERG transported⁽¹³⁰⁾. Interestingly, it is up-regulated chronobiologically just before meal times⁽¹⁷⁵⁾. The rat and human orthologues are interchangeable⁽¹⁷⁸⁾. Tissue levels of ERG depend on an exogenous supply⁽¹⁷⁹⁾, but are then well correlated with the expression levels of SLC22A4^(3,180). SLC22A4 expresses well even in microbial systems⁽¹⁸¹⁾, and is widely tolerant of amino acid substitutions⁽¹⁸²⁾. As yet, no other transporter with significant activity for ERG in humans is known, making it a potentially interesting drug target^(183,184).

Expression patterns

SLC22A4 is known to express in the intestinal lumen⁽¹⁸⁵⁾, acting to take up ERG, as well as some xenobiotics including pyrrolamine, quinidine and verapamil, and having multiple known but weak inhibitors.

Fig. 4 shows the expression of the transcript for SLC22A4 in fifty-six cell lines using previous data⁽¹¹⁹⁾ taken from the human protein atlas⁽¹⁸⁶⁾, indicating a range in expression levels between different cell lines of more than 4000-fold, a number not atypical for human transporters⁽¹¹⁹⁾. Tissue expression data are given in Fig. S4 of O’Hagan *et al.*⁽¹¹⁹⁾.

The intracellular expression patterns are as yet uncertain, with early claims for a mitochondrial expression^(86,187–190) being based on very weak and contradictory evidence⁽⁸⁾. However, while the cellular uptake of ERG does require plasma membrane expression, the latest version of the protein atlas indicates mitochondrial expression as well⁽¹⁹¹⁾. However, as is well known, antibody specificities are rarely either known or absolute^(192–198). Thus, relying on antibody evidence alone is rather hazardous, and, as mentioned before⁽⁸⁾, mitochondrial transporters have an SLC25 family designation^(199,200). Definitive measurements on the uptake or otherwise of ERG into isolated mitochondria, or indeed into other organisms that cannot make it, are eagerly awaited.

Evolution and phylogenetic distribution of SLC22A4

Phylogenetic analyses^(201,202) indicate that homologues of SLC22A4, a relative of the major facilitator superfamily 2, exist only in vertebrate animals, especially mammals, birds and fish, with occasional examples in reptiles (for example, *Xenopus* spp.).

In practice, it appears that the transporters responsible for the uptake of some 85 % of pharmaceutical drugs actually evolved to





Fig. 4. Differences in expression of SLC22A4 transcript in a series of mammalian cell lines. Data are from Thul *et al.*⁽¹⁸⁶⁾ and O'Hagan *et al.*⁽¹¹⁹⁾. For a colour figure, see the online version of the paper.

take up exogenous natural products⁽²⁰³⁾. In the case of the cocaine transporter⁽²⁰⁴⁾, a simple narrative can serve to explain how a cocaine-mediated ability to outrun a predator such as a sabre-tooth tiger can rather obviously be selected provided the bioactive substance is actually taken up by the host. More generally, the ability to transport exogenous natural products is likely to be selected for when these confer fitness benefits on the host⁽²⁰⁵⁾, and this probably underpins the finding that successful, marketed drugs are indeed similar to (mainly 'secondary') natural products⁽²⁰³⁾.


Oxidative stress

Oxidative stress is widespread to the point of ubiquity in chronic, inflammatory diseases^(206,207), with over fifty papers having the words 'oxidative', 'stress' and 'review' in their titles at PubMed in 2018 alone! It can occur when oxygen tension is low and respiratory chains are over-reduced such that they reduce O₂ with one electron to superoxide or two electrons to H₂O₂, instead of the four that are used during the reduction of dioxygen to water by cytochrome oxidase⁽²⁰⁸⁾ (Fig. 5). Peroxides are also produced *in vivo* by various oxidases and peroxidases, such as xanthine oxidase, by reduction of dioxygen (for example, Babior⁽²⁰⁹⁾, Cave *et al.*⁽²¹⁰⁾ and Bedard & Krause⁽²¹¹⁾).

While H₂O₂ and superoxide are certainly capable of effecting unwanted oxidations, it is the hydroxyl radical that is the key. Thus an important reaction of H₂O₂ with (free or poorly liganded) Fe(II) is the Fenton reaction^(208,212,213), leading to the very reactive and damaging hydroxyl radical (OH[•]):



which can react within nanoseconds with anything adjacent. The role of Fe is absolutely vital here^(208,213). Superoxide can also react with ferric Fe in the Haber–Weiss reaction^(214–216) to produce Fe(II) again, thereby effecting redox cycling, and meaning the 'iron' is catalytic (Fig. 6):



In addition O₂^{•-} can release 'catalytic' Fe from Fe-S clusters in certain proteins and from ferritin^(208,217), another way in which it can promote the Fenton reaction. Note that other reactions can produce OH[•] anaerobically⁽²¹⁸⁾. Because OH[•] is so reactive it is not really observable in its free form; its action is detected via products of molecules with which it has reacted. These include 8-oxo-guanine derivatives⁽²¹⁹⁾, nitrotyrosine^(220–222) (itself formed from peroxyxynitrite^(223,224), possibly formed more commonly via superoxide^(225,226)), 4-hydroxy-nonenal⁽²²⁷⁾, and many others reviewed previously⁽²⁰⁸⁾. In evaluating the antioxidant potency of ERG or anything else, it is molecules such as these that are normally assessed. Although the literature is somewhat scattered and heterogeneous, it seems clear that as well as hydroxyl radicals^(228–232), ERG can also react with and detoxify, or prevent the formation of, singlet oxygen^(233–242), ozone⁽²⁴³⁾, superoxide^(231,241,244–246), peroxide^(32,124,247,248), hypochlorite^(32,232,249) and peroxyxynitrite^(224,231,250,251). Consequently, it is a potent antioxidant.




Fig. 5. Superoxide and peroxide are produced by 1- and 2-electron reduction of dioxygen by the mammalian respiratory chain. For a colour figure, see the online version of the paper.




Fig. 6. Catalytic roles of unliganded iron in hydroxyl radical production via the Fenton and Haber–Weiss reactions. This can be stopped by ensuring that iron is fully liganded. For a colour figure, see the online version of the paper.

Roles in the producer

Although it is not *a priori* certain that they would be the same in both producer and consumer organisms, it is of interest, before looking at higher organisms, to consider the roles of ERG in the producer organisms themselves. In the case of *C. purpurea*, the ERG serves as an antioxidant to neutralise a plant host defence response based on H₂O₂ that would otherwise inhibit the production of its conidia^(252,253). In *M. tuberculosis* and other mycobacteria⁽²⁵⁴⁾, and also in other actinobacteria⁽²⁵⁵⁾ and in fungi^(247,256,257), it is clear that ERG can have a role as an antioxidant^(66,258–260) and also act as a buffer against reductive stress⁽²⁶¹⁾. In nature many organisms can be subjected to oxidative stress, and produce a variety of molecules to combat it^(262–270). This also seems true of mushrooms^(271,272), where ERG is typically the main antioxidant^(273–275), and where it may also inhibit the oxidative enzyme tyrosinase⁽²⁷⁶⁾. Given suggestions that the ‘purpose’ of secondary metabolite formation is to serve as a signalling molecule in different cells of the producer organism, i.e. as a pheromone⁽²⁷⁷⁾, it is interesting to note that this may also involve crosstalk of ERG⁽³⁷⁾, due in part to the complex networks in which it may be embedded⁽²⁷⁸⁾. The same is true of the imidazole thiol-containing othiothiol^(279,280). In a similar vein, and although outwith our scope here, we note the potential of other antioxidant natural products such as curcumin^(281–286).

Nutritional sources

Betaines are generally seen as nutritionally beneficial⁽²⁸⁷⁾, and many are ‘compatible solutes’^(288–293), defined as solutes whose accumulation assists the survival of the organism when undergoing various kinds of stress such as osmotic or thermal stress. However, of these, only ERG is seen as a major antioxidant. Although a variety of foodstuffs such as oats^(294,295) contain ERG because they take it up from exogenous sources, it is really mushrooms that are the prime sources for humans^(18,294). Indeed, ERG has been proposed as a nutritional biomarker for mushroom consumption^(296,297), albeit that different mushrooms typically contain different amounts^(275,298–300), and these can vary with physiological or environmental conditions^(301–305). Those with the highest amounts include oyster mushrooms (*Pleurotus* spp., up to 4 mg/g DM)⁽³⁰⁶⁾, the golden oyster *Pleurotus citrinopileatus* with 10–65 mg/g DM^(307,308), and shiitake (*Lentinula edodes*, about 1 mg/g DM), while of those more common outside Asia, porcini or ceps (*Boletus edulis*, > 7 mg/g DM), stand out^(6,294,300). However, even common field or ‘button’ mushrooms, *Agaricus bisporus*, contain some 0.4 mg/g DM^(275,299,300,309). Note too that tempe(h), the result of a solid substrate *Rhizopus oligosporus* fermentation^(310–314), also contains high levels of ERG⁽⁶⁾. Mushrooms may also be a significant benefit to those seeking a meat-free diet as they can be made to share certain organoleptic features with meat^(315,316). Notably, ‘the production of cultivated, edible mushrooms worldwide has increased more than 30-fold since 1978, whereas the population has only increased by about 1.7-fold during the same period’^(10,317).

Some studies that have demonstrated nutritional/health benefits of mushrooms and their antioxidant activity^(125,271,318–351) did not always seek to deconstruct these into their constituents such as ERG, but ERG is clearly the chief mushroom antioxidant. We note too that some effects may be dependent on the composition of the gut microflora⁽³⁵²⁾, that are of course themselves likely to be changed by ERG, just as they are by many other non-antibiotic drugs⁽³⁵³⁾.

Safety

Producer organisms such as mushrooms are well known to make many secondary metabolites, some of which can be highly toxic^(354–356) and by various mechanisms⁽³⁵⁷⁾. Notwithstanding the highly variable intake between individuals⁽³⁵⁸⁾, however, a number of high-dose studies have indicated that ERG is safe for mammalian consumption at levels far in excess of those likely to be encountered in foodstuffs^(125,131,359,360), and it has been declared safe by relevant committees such as those of the European Food Standards Agency^(361,362). It also lacks any detectable mutagenicity or genotoxicity in such assays, even at very high doses^(363,364).

Analytcs

Leaving aside early efforts such as the colorimetric methods of Hunter⁽³⁶⁵⁾, of Melville and colleagues^(76,85,366) and of Carlsson *et al.*⁽³⁶⁷⁾, a variety of analytical methods have been proposed⁽⁴⁾, mostly involving capillary electrophoresis^(368,369) or chromatography^(368,370–372) coupled to absorbance^(373,374), fluorescence detection^(375–378), electrochemical detection⁽³⁷⁹⁾ or MS^(72,127,256,368,378,380–382). A useful feature is that ERG is unusually stable, in that anhydrous ERG decomposes only at 275–276°C⁽⁷²⁾, allowing its isolation at temperatures close to that of boiling water⁽⁷²⁾. As judged by the reversibility of its acid–base titration⁽³⁸³⁾, it is also stable to extremes of pH.

Industrial purification of glycine betaine is done by extraction with water⁽³⁸⁴⁾ and subsequent ion exchange chromatography^(384,385), which can be done in simulated moving bed fashion⁽³⁸⁶⁾. Glycine betaine can then be crystallised⁽³⁸⁴⁾. As glycine betaine is structurally similar to ERG, this straightforward industrial process could potentially be adapted for ERG.

Serum and other concentrations

While most ERG is inside erythrocytes in whole blood^(6,121,122,129,387), there have been a number of measurements of ERG concentrations in serum. Unsurprisingly it varies with diet^(388,389), starvation⁽³⁹⁰⁾, age^(391,392) and other factors, including diseases of oxidative stress⁽³⁹³⁾, with typical values of 20–100 µg/ml. A detailed list is provided by Cheah & Halliwell⁽⁴⁾; a smaller listing is given in Table 3. Interestingly, ERG is also present in seminal fluid^(394–396) and human breast milk⁽⁶⁾. Any possible correlation with male fertility⁽³⁹⁷⁾ seems not to have been established, though there were no negative effects⁽³⁹⁸⁾, and ERG improved oocyte quality and maturation

Table 3. Concentrations of ergothioneine in human serum

	Concentration	Study
Crohn's disease	7 µg/ml	(401)
Healthy volunteer	38 µg/ml	(401)
Healthy 1–10 years	15–20 µg/ml	(387)
Healthy 11–18 years	37 µg/ml	(387)
Healthy 19–50 years	23–30 µg/ml	(387)
Healthy middle-aged and older	Median 1 µM = 229 ng/ml, range 0.36–3.08 µM*	Inverse correlation with age (571)
Mice on normal diet	58 µg/ml	(131)

*Molecular weight = 229.3, so 1 mM = 229 mg/l.

in cows and sheep⁽³⁹⁹⁾. ERG is also present in eye lens, where its concentration is lower in individuals with cataracts⁽⁴⁰⁰⁾.

Metabolism and excretion

ERG is metabolised and excreted only slowly^(360,371,401,402). In a recent and detailed study, Cheah *et al.*⁽³⁶⁰⁾ administered 5–25 mg daily doses of ERG to human volunteers for 7 d. There was little urinary excretion (<4 %), and the main metabolites were hercynine, plus lesser amounts of *S*-methyl-ERG, whose concentrations were well correlated with the level of ERG and the dose of ERG given. Similar observations were made in mice⁽¹³¹⁾. Various other biomarkers of oxidative stress (for example, 8-iso-PGF2α from lipid peroxidation) were lowered concomitantly in the human study, attesting to the antioxidant functions of ERG *in vivo*, although in this case the healthy young subjects were probably not suffering from oxidative stress. There was also quite some variation in uptake between individuals, presumably reflecting variation in their expression of SLC22A4. *Agrobacterium radiobacter*⁽⁴⁰³⁾ and other bacteria^(404–409) contain an ergothionease that degrades ERG to thiolurocanic acid (3-(1H-imidazol-5-yl)prop-2-enethioic *S*-acid) and trimethylamine, also implying that such cells possess one or more transporters for ERG. The thiolurocanic acid can be further degraded to glutamate⁽⁴¹⁰⁾.

Apparent fitness benefits and bioactivities of ERG and the role of SLC22A4

Given the great technical difficulties associated, because of its ubiquity, with withholding ergothioneine from a human or animal diet, one means of 'removing' ERG from a host is to remove the ERG transporter by genetic means. This has in fact been done in mice⁽⁴⁰¹⁾; such SLC22A4^{-/-} mice had immeasurably low levels of ERG relative to controls, and were much more sensitive to oxidative stress than were the wild type. Similar effects were observed in *Caenorhabditis elegans*⁽⁴¹¹⁾. Polymorphisms in SLC22A4, of which there can be many^(177,412–415), under selection⁽⁴¹⁶⁾, have also been associated with ischaemic stroke⁽⁴¹⁷⁾, erythroid differentiation⁽⁴¹⁸⁾, hearing loss⁽⁴¹²⁾, rheumatoid arthritis^(126,180,419–427), lupus⁽⁴²⁸⁾, Crohn's disease^(401,429–436), hearing loss⁽⁴¹²⁾, type 1 diabetes⁽⁴³⁷⁾ and diabetic embryopathy⁽⁴³⁸⁾. The expression of SLC22A4 can itself be modulated by other factors, including by PPAR-α

activity⁽⁴³⁹⁾. The very diversity of these diseases speaks naturally to a broad and common underlying cause, the easiest of which involves mechanisms of oxidative stress, inflammation and cell death.

Mechanisms of action

It has become common to discover a binding of a small molecule to another molecule such as a protein, and assume that this interaction, leading to activation or inhibition of the target, constitutes 'the' mechanism of action of the small molecule at a physiological level. Unfortunately this is rarely the case, and known drugs, despite often being selected for inhibiting potentially a specific molecular target⁽¹⁴⁷⁾, have, on average, six known binding targets⁽⁴⁴⁰⁾. When these interactions ramify through a complex and non-linear biochemical network it can be hard to apportion the effects of a small exogenous molecule between the various interactions^(441–443).

A standard view of systems or network biology (for example, Kell⁽⁴⁴⁴⁾ and Kell & Knowles⁽⁴⁴⁵⁾) develops these ideas in four stages. In stages 1 and 2 we simply recognise the actors and the interactions between them at a qualitative level. Stages 3 and 4 then seek to describe the equations reflecting individual steps and the values of the parameters of those equations. Armed with these we can make an ordinary or, if spatial resolution within a compartment is required, a partial differential equation model of the system. This can then be run and the sensitivities of each step determined^(446–448). We are very far from this last part, and so studies of the effects of ERG have in general⁽⁴⁴⁹⁾ been rather descriptive in nature. Many have been at the level of processes rather than mechanisms, and they have been reviewed in detail^(3,360). Table 4 and Fig. 7 provide a selection of determinands that have been shown to change their concentrations or activities when ERG is added to the system of interest. In many cases it is not at all clear what the proximate mechanisms are. Note as just one example that the highly promiscuous transcription factor NF-κB^(450–452), whose frequency-dependent activity directly affects the expression of hundreds of enzymes^(453,454), is itself redox-sensitive^(455–458), and is affected by ERG^(459,460), while NF-κB increases the rates of SLC22A4 transcription⁽⁴¹⁹⁾. Thus, deconstructing the many possible direct and consequential interactions of ERG with proteins, *v.* whether these are simply a consequence of its provision of a more reducing environment, is likely to be a formidable task. In a similar vein, the effects of ERG on the microbiomes of the hosts are likely to be significant, but do not yet seem to have been studied.

It seems clear that the chief role of ERG, via a variety of mechanisms, including directly, is to serve as an antioxidant and cellular protectant against various kinds of reactive oxygen and N species.

Cytoprotection

At a high level, ERG is seen as an excellent cytoprotectant against all kinds of cellular insults^(3,4,6,124). We split some of the more detailed analyses into subdivisions in the following few sections.

Table 4. Biological properties whose expression or activity varies on exposure of a biological system to ergothioneine (ERG) or a modulation of SLC22A4 activity

Determinand	System	Comments	Selected reference(s)
Cataract formation induced by glucocorticoid	Developing chick embryo	ERG inhibits	(572)
Cell death	Human neuronal hybridoma cell line N-18-RE-105	H ₂ O ₂ challenge	(251)
	<i>Caenorhabditis elegans</i>	Protection from amyloid-β-induced cell death	(521)
Cell injury	Rat pheochromocytoma cells	Methylglyoxal challenge	(573)
Cell proliferation	K562 cells	Involvement of SLC22A4	(418)
	Caco-2 cells	Involvement of SLC22A4	(429)
Diabetic embryopathy	Rats	ERG reduced it to control levels	(574)
DNA damage in mitochondria	HeLa, RAW 264-7, HaCaT, PC12 cells	siRNA knockdown of SLC22A4	(3)
Embryo development	Sheep	Improvement, despite non-uptake of ERG	(399,575)
Embryo quality and maturation	Cows	Improvement	(576)
Excitotoxicity caused by <i>N</i> -methyl-D-aspartate	Rat	Protection by ERG	(577)
Glycolysis	Erythrocytes	Preservation of lactate production during starvation	(578)
Hepatocyte injury induced by CCl ₄	Hepatocytes	Protection, also by β-hydroxy derivative	(579)
Immune modulation	Mouse macrophages	Skewing towards a Th17 response	(580)
Immunotherapy	Tumour cells	Improved vaccine responses by dampening cytotoxic T-lymphocyte suppression	(581)
IL-8	Alveolar macrophages	H ₂ O ₂ and TNF-α induction. Possible intermediacy of NF-κB	(460)
Fe incorporation into protoporphyrin	Erythrocyte fractions	Said to keep Fe reduced; does not seem to have been confirmed	(562)
Kidney fibrosis	Mice	Worsens during chronic kidney disease if SLC22A4 removed	(582)
Lipid peroxidation	HeLa, RAW 264-7, HaCaT, PC12 cells	siRNA knockdown of SLC22A4	(3)
	<i>In vitro</i>	Free radical initiated with anthracyclines	(583)
Lung injury	Rats	Cytokine treatment; damage prevented by ERG	(505)
Memory	C57BL/6J mice	Attenuates memory loss induced by D-galactose; synergistic with melatonin	(584)
Metal ion chelation	Co ⁺⁺ , Cu ⁺⁺ , Ni ⁺⁺ , Zn ⁺⁺	Direct and within enzymes	(527)
	Cu ⁺⁺ >Hg ⁺⁺ >Zn ⁺⁺ >	IR measurements	(585)
	Cd ⁺⁺ >Co ⁺⁺ >Zn ⁺⁺		
	Cu ⁺⁺	NMR	(586)
	Cu ⁺⁺	Chelation prevents DNA damage	(473)
	Cu ⁺⁺	Chelation prevents DNA damage	(472)
	Hg ⁺⁺	In intact erythrocytes, after glutathione	(587)
Mutagenesis protection	Multiple	Often involving singlet oxygen	(588–591)
Neuronal differentiation	Neural progenitor cells	ERG stimulated differentiation	(592)
NF-κB	MH7A cells	Affects SLC22A4 expression	(419)
Nrf2	HaCaT skin cells	Anti-apoptotic following UV irradiation	(549)
S-nitrosoglutathione catabolism	<i>In vitro</i>	ERG stimulates	(593)
S6K1 mTOR and neurotrophin 4/5-TrkB	Neural stem cells	Rapid induction after ERG exposure	(594)
Sickle cell anaemia		ERG is protective	(595)
SIRT1 and SIRT6	Endothelial cells	Protection v. glucose-induced senescence	(482)
Sperm motility	Boars	Protection v. Cu ⁺⁺ inhibition	(596)

siRNA, small interfering RNA; mTOR, mammalian target of rapamycin; SIRT, sirtuin.

Oxidative stress

Oxidative stress can be defined and measured in many ways^(461–468), but is broadly taken to involve a dysregulation in the various redox systems of the organism of interest, coupled to the production of various ‘reactive oxygen species’, principally peroxide, superoxide, hydroxyl radical, and singlet oxygen. ERG has been shown to decrease oxidative stress in the liver and kidney of rats⁽⁴⁶⁹⁾, rescued cells from β-amyloid-induced apoptotic death⁽²³¹⁾, protected against palmitic acid-induced cell death⁽⁴⁷⁰⁾, mercuric chloride-induced cellular dysfunction⁽⁴⁷¹⁾, and prevented Cu-induced oxidative damage to DNA^(472,473). It is protective against the oxidation of

various kinds of molecule^(251,474), including astaxanthin⁽⁴⁷⁵⁾, and accumulates in a guinea-pig model of non-alcoholic fatty liver disease⁽⁴⁷⁶⁾, massively so in mouse models of myocardial infarction and heart failure⁽⁴⁷⁷⁾, and in a rat model of optic nerve crush⁽⁴⁷⁸⁾. It serves to resist H₂O₂-induced cell death⁽⁴⁷⁹⁾, pyrogallol-induced toxicity⁽¹²⁴⁾, cisplatin-⁽⁴⁸⁰⁾ or oxaliplatin-induced⁽⁴⁸¹⁾ toxicity, glucose-induced senescence^(246,482), as well as lipopolysaccharide-induced inflammation⁽⁴⁸³⁾. In particular, it is protective against ischaemia-reperfusion injury^(484–486), and may have uses in prolonging the lifetime of stored blood⁽⁴⁸⁷⁾. Probably such antioxidant activities are at the core of its biological benefits.




Fig. 7. Overview of some of the effects of ergothioneine in mammalian systems. For a colour figure, see the online version of the paper.

Ergothioneine as a therapeutic for chronic inflammatory diseases?

Inflammation and oxidative stress go hand in hand⁽³⁾, since reactive oxygen species (and materials such as bacterial cell wall components that can lead to their generation^(206,488)), lead to the production of inflammatory cytokines. Although a great many chronic, inflammatory diseases are recognised as having an oxidative stress component⁽²²³⁾, the history of treating them with antioxidants such as ascorbate has largely been a litany of failure, with the treatment arm often even giving worse prognoses than the placebo^(6,223,489–501). Arguably this is because nominally antioxidant molecules such as ascorbate have complex, multi-electron redox chemistry, and can in fact act as pro-oxidants^(502,503), especially in the presence of free Fe^(208,213) or Cu⁽⁵⁰⁴⁾. This is not an issue with ERG, however, partly because it can chelate them, and ERG levels are decreased, or ERG has been proposed as a useful antioxidant, in diseases such as acute respiratory distress syndrome⁽⁵⁰⁵⁾, CVD^(506,507), chronic obstructive pulmonary disease⁽²²³⁾, pre-eclampsia⁽⁸⁾ (see also Turner *et al.*⁽¹²⁸⁾), overhydrated hereditary

stomatocytosis⁽⁵⁰⁸⁾, and is significantly lowered in others such as certain leukaemias^(121,122). The evidence for this comes from a variety of sources, including metabolite measurements in human subjects^(121,122,509), and intervention studies in both animals⁽⁵⁰⁵⁾ and cell lines^(3,124,506). In particular, there is a notable relationship between ERG consumption and longevity (Fig. 6 in Beelman *et al.*⁽¹⁰⁾), while in a 3236-participant Swedish study, ERG was the metabolite most strongly connected to a ‘health conscious food pattern’ and was associated with a lower risk of coronary disease (hazard ratio (HR) per 1 sd increment of ERG, HR = 0.85; *P* = 0.01), cardiovascular mortality (HR = 0.79; *P* = 0.002) and overall mortality (HR = 0.86; *P* = 4 × 10⁻⁵)⁽⁵⁰⁹⁾.

Neurological diseases and cognitive function

Mushrooms have been shown to have very substantial effects on cognitive function^(341,348,510–513), and this is mainly ascribed to their ERG content, that also decreases with the age of the consumer⁽³⁹¹⁾. The kinds of evidence include both double-blind, placebo-controlled clinical trials⁽³⁴¹⁾ and observational

(cross-sectional) studies in both humans^(348,510–512) and rodents⁽⁵¹³⁾. Thus, consuming 1–5 mushroom servings per week was associated with a halving of the incidence of mild cognitive impairment (a precursor of Alzheimer's dementia), while intake of nine servings per week was associated with a five-fold decrease⁽³⁴⁸⁾. Note, however, that at least one mushroom trial indicated no measurable benefits in healthy young physical education students⁽⁵¹⁴⁾. Brain and serum ERG levels are also markedly different in Parkinson's disease⁽⁵¹⁵⁾, reviewed in Hang *et al.*⁽⁵¹⁶⁾, Shao & Le⁽⁵¹⁷⁾ and Shah & Duda⁽⁵¹⁸⁾, and even in sudden infant death syndrome⁽⁵¹⁹⁾, and ERG has been shown to be protective against β -amyloid-induced neuronal injury⁽⁵²⁰⁾ and cytotoxicity⁽⁵²¹⁾. It can also act as an antidepressant⁽⁵²²⁾. The evidence for this comes from direct studies⁽⁵²⁰⁾ and feeding experiments⁽⁵²²⁾ in mice, as well as via the reduction of β -amyloid peptide in a transgenic *C. elegans* model⁽⁵²¹⁾. As mentioned above, SLC22A4 polymorphisms are associated with ischaemic stroke⁽⁴¹⁷⁾.

Use of ergothioneine as an antioxidant in processed foodstuffs

Just as living beings exploit antioxidants, most foodstuffs can also be oxidised to produce taints, rancidity or other undesirable products^(523–525), often via the Fenton reaction^(208,526). ERG inhibits polyphenoloxidases⁽⁵²⁷⁾, and thus ERG has been used in the feed of the shrimp *Marsupenaeus japonicus* to prevent melanosis during storage⁽⁵²⁸⁾, while ERG-rich mushroom extract has also been used to prevent melanosis in post-harvest storage of the crab *Chionoecetes japonicus*⁽⁵²⁹⁾. Thus, one can also envisage a role for ERG, whether natural or added, in extending shelf lives and commercial value^(245,328,475,528–539). The thermostability of ERG is of particular importance here.

Use of ergothioneine in cosmetics

Just as processed foodstuffs 'age', so do tissues such as the skin, and although the same principles apply⁽⁵⁴⁰⁾, it is common to refer to nutraceuticals that are also aimed at having cosmetic benefits as 'cosmeceuticals'^(541–543). Here too, ERG has been widely used^(543–547), since much skin damage is caused by UV-mediated reactive oxygen species production⁽⁵⁴⁸⁾; indeed, ERG is known as a skin protectant^(240–244,549–551).

Role of ergothioneine as a cofactor?

Although it is possible that the role of ERG lies simply in being an antioxidant capable of mopping up hydroxyl radicals and other reactive oxygen species, especially in prokaryotes^(36,66,93,254,255,258–260,552,553), the roles of most other vitamins involve interaction with proteins, often as cofactors. This is also true for mycothiol^(73,554–556), though that molecule can also serve as a signal and nutrient resource⁽⁵⁵⁷⁾. However, despite many hypotheses^(558,559), the only example of ERG acting as a cofactor known to date is an involvement in the biosynthesis of lincomycin^(560,561). An early paper⁽⁵⁶²⁾ implying an involvement of ERG in the maintenance of a reduced state of

Fe in Hb, although apparently accurate, does not seem to have been followed up to date.

Conclusions

There is increasing awareness that health may be enhanced via the consumption of substances that either have no recommended daily intake or are taken at levels greater than normal, and such substances are commonly referred to as nutraceuticals. ERG, a potent and effective antioxidant, seems to be an important nutraceutical, and we rehearse a very broad literature, involving a great many cells, tissues and organisms, to that effect. The chief source of ERG in the human diet is mushrooms (usually the fruiting bodies of Basidiomycetes). The fact that a specific transporter known as SLC22A4 has evolved and been selected to effect ERG uptake in all known animals suggests strongly that ERG is of benefit to its consumers. While the evidence that ERG may be a useful nutraceutical as a preventive or palliative for various inflammatory diseases is extensive, it is mostly circumstantial rather than definitive, though many examples exist of the benefits of mushrooms in combating the results of oxidative stress.

Without mechanisms, finding that the concentration of a dietary metabolite X is low in disease Y does not mean that giving it might be of benefit in the prevention, delay or cure of that disease, although cases can clearly be made when X is a vitamin, or oxidative stress is known to be a damaging component of Y^(8,348). Thus far, we lack examples in which ERG is found both to be low in individuals with a particular syndrome and where exogenous administration effects functional improvements, although – as reviewed above – we often have one or the other.

To assess definitively any health benefits of ERG, the 'gold standard' of randomised controlled trials may take time and money, but – as with mushrooms^(335,563) – are beginning. One trial with pure ERG has been registered⁽⁵⁶⁴⁾.

Note added in proof

A recent paper indicates that ERG relieves the effects seen in a rat model of the pregnancy disorder pre-eclampsia⁽⁵⁹⁷⁾.

Acknowledgements

We thank the Biotechnology and Biological Sciences Research Council (BBSRC) (grants no. BB/R000093/1 and no. BB/P009042/1) and the Novo Nordisk Foundation (grant no. NNF10CC1016517) for financial support.

D. B. K. decided to bring together the multifaceted contributions of the various authors listed. Their previous contributions to ergothioneine and antioxidant biology may be seen in the references cited. All authors contributed to and approved the final manuscript.

I. B., S. A. v. d. H. and D. B. K. are named inventors on a patent application involving the biotechnological production of L-(+)-ergothioneine in yeast. For the other authors, there are no conflicts of interest.

References

- Kraemer K, Semba RD, Eggersdorfer M, *et al.* (2012) Introduction: the diverse and essential biological functions of vitamins. *Ann Nutr Metab* **61**, 185–191.
- Semba RD (2012) The discovery of the vitamins. *Int J Vitam Nutr Res* **82**, 310–315.
- Paul BD & Snyder SH (2010) The unusual amino acid L-ergothioneine is a physiologic cytoprotectant. *Cell Death Differ* **17**, 1134–1140.
- Cheah IK & Halliwell B (2012) Ergothioneine; antioxidant potential, physiological function and role in disease. *Biochim Biophys Acta* **1822**, 784–793.
- Halliwell B, Cheah IK & Drum CL (2016) Ergothioneine, an adaptive antioxidant for the protection of injured tissues? A hypothesis. *Biochem Biophys Res Commun* **470**, 245–250.
- Halliwell B, Cheah IK & Tang RMY (2018) Ergothioneine – a diet-derived antioxidant with therapeutic potential. *FEBS Lett* **592**, 3357–3366.
- Ames BN (2018) Prolonging healthy aging: longevity vitamins and proteins. *Proc Natl Acad Sci U S A* **115**, 10836–10844.
- Kerley RN, McCarthy C, Kell DB, *et al.* (2018) The potential therapeutic effects of ergothioneine in pre-eclampsia. *Free Radic Biol Med* **117**, 145–157.
- Anonymous (2015) L-Ergothioneine. <http://www.tetrahedron.fr/products/research/l-ergothioneine> (accessed August 2019).
- Beelman RB, Kalaras MD, John P, *et al.* (2019) Micronutrients and bioactive compounds in mushrooms: a recipe for healthy aging? *Nutr Today* **54**, 16–22.
- Cencic A & Chingwaru W (2010) The role of functional foods, nutraceuticals, and food supplements in intestinal health. *Nutrients* **2**, 611–625.
- Bahadoran Z, Mirmiran P & Azizi F (2013) Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. *J Diabetes Metab Disord* **12**, 43.
- Ogle WO, Speisman RB & Ormerod BK (2013) Potential of treating age-related depression and cognitive decline with nutraceutical approaches: a mini-review. *Gerontology* **59**, 23–31.
- Ragle RL & Sawitzke AD (2012) Nutraceuticals in the management of osteoarthritis: a critical review. *Drugs Aging* **29**, 717–731.
- Chauhan B, Kumar G, Kalam N, *et al.* (2013) Current concepts and prospects of herbal nutraceutical: A review. *J Adv Pharm Technol Res* **4**, 4–8.
- Borghi C & Cicero AF (2017) Nutraceuticals with a clinically detectable blood pressure-lowering effect: a review of available randomized clinical trials and their meta-analyses. *Br J Clin Pharmacol* **83**, 163–171.
- Aruoma OI, Coles LS, Landes B, *et al.* (2012) Functional benefits of ergothioneine and fruit- and vegetable-derived nutraceuticals: overview of the supplemental issue contents. *Prev Med* **54**, Suppl., S4–S8.
- Rathore H, Prasad S & Sharma S (2017) Mushroom nutraceuticals for improved nutrition and better human health: a review. *PharmaNutrition* **5**, 35–46.
- Espín JC, García-Conesa MT & Tomás-Barberán FA (2007) Nutraceuticals: facts and fiction. *Phytochemistry* **68**, 2986–3008.
- Sharif MK & Khalid R (2018) Nutraceuticals: myths versus realities. In *Therapeutic Foods*, vol. 8, pp. 3–21 [AM Holban and AM Grumezescu, editors]. Cambridge, MA: Academy Press.
- Singh S, Razak MA, Sangam SR, *et al.* (2018) The impact of functional food and nutraceuticals in health. In *Therapeutic Foods*, vol. 8, pp. 23–47 [AM Holban and AM Grumezescu, editors]. Cambridge, MA: Academy Press.
- Spindler SR, Mote PL & Flegal JM (2014) Lifespan effects of simple and complex nutraceutical combinations fed isocalorically to mice. *Age (Dordr)* **36**, 705–718.
- Poddar K, Kolge S, Bezman L, *et al.* (2011) Nutraceutical supplements for weight loss: a systematic review. *Nutr Clin Pract* **26**, 539–552.
- Camfield DA, Sarris J & Berk M (2011) Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. *Prog Neuropsychopharmacol Biol Psychiatry* **35**, 887–895.
- Goggs R, Vaughan-Thomas A, Clegg PD, *et al.* (2005) Nutraceutical therapies for degenerative joint diseases: a critical review. *Crit Rev Food Sci Nutr* **45**, 145–164.
- Naveen J & Baskaran V (2018) Antidiabetic plant-derived nutraceuticals: a critical review. *Eur J Nutr* **57**, 1275–1299.
- Orr SL & Venkateswaran S (2014) Nutraceuticals in the prophylaxis of pediatric migraine: evidence-based review and recommendations. *Cephalalgia* **34**, 568–583.
- Orr SL (2016) Diet and nutraceutical interventions for headache management: a review of the evidence. *Cephalalgia* **36**, 1112–1133.
- Tanret C (1909) A new base taken from rye ergot, ergothioneine. *Ann Chim Phys* **18**, 114–124.
- Tanret C (1909) The new base drawn from rye ergot, ergothioneine. *Cr Hebd Acad Sci* **149**, 222–224.
- Barger G & Ewins AJ (1911) The constitution of ergothioneine: a betaine related to histidine. *J Chem Soc* **99**, 2336–2341.
- Servillo L, Castaldo D, Casale R, *et al.* (2015) An uncommon redox behavior sheds light on the cellular antioxidant properties of ergothioneine. *Free Radic Biol Med* **79**, 228–236.
- Franzoni F, Cognato R, Galetta F, *et al.* (2006) An *in vitro* study on the free radical scavenging capacity of ergothioneine: comparison with reduced glutathione, uric acid and trolox. *Biomed Pharmacother* **60**, 453–457.
- Hand CE, Taylor NJ & Honek JF (2005) *Ab initio* studies of the properties of intracellular thiols ergothioneine and ovoidiol. *Bioorg Med Chem Lett* **15**, 1357–1360.
- Hand CE & Honek JF (2005) Biological chemistry of naturally occurring thiols of microbial and marine origin. *J Nat Prod* **68**, 293–308.
- Fahey RC (2013) Glutathione analogs in prokaryotes. *Biochim Biophys Acta* **1830**, 3182–3198.
- Sheridan KJ, Dolan SK & Doyle S (2015) Endogenous cross-talk of fungal metabolites. *Front Microbiol* **5**, 732.
- Fahey RC (2001) Novel thiols of prokaryotes. *Annu Rev Microbiol* **55**, 333–356.
- Jacob C (2006) A scent of therapy: pharmacological implications of natural products containing redox-active sulfur atoms. *Nat Prod Rep* **23**, 851–863.
- Clark WM (1960) *Oxidation-reduction Potentials of Organic Systems*. Baltimore, MD: The Williams and Wilkins Co.
- Walz D (1979) Thermodynamics of oxidation–reduction reactions and its application to bioenergetics. *Biochim Biophys Acta* **505**, 279–353.
- Reyes AM, Pedre B, De Armas MI, *et al.* (2018) Chemistry and redox biology of mycothiol. *Antioxid Redox Signal* **28**, 487–504.
- Sharma SV, Van Laer K, Messens J, *et al.* (2016) Thiol redox and pK_a properties of mycothiol, the predominant low-molecular-weight thiol cofactor in the actinomycetes. *ChemBiochemistry* **17**, 1689–1692.
- Kell DB & Morris JG (1979) Oxidation–reduction properties of coenzyme M (2-mercaptoethane sulphonate) at the mercury electrode. *FEBS Lett* **108**, 481–484.

45. Achouba A, Dumas P, Ouellet N, *et al.* (2019) Selenoneine is a major selenium species in beluga skin and red blood cells of Inuit from Nunavik. *Chemosphere* **229**, 549–558.
46. Little M, Achouba A, Dumas P, *et al.* (2019) Determinants of selenoneine concentration in red blood cells of Inuit from Nunavik (Northern Quebec, Canada). *Environ Int* **127**, 243–252.
47. Turrini NG, Kroepfl N, Jensen KB, *et al.* (2018) Biosynthesis and isolation of selenoneine from genetically modified fission yeast. *Metallomics* **10**, 1532–1538.
48. Rohn I, Kroepfl N, Bornhorst J, *et al.* (2019) Side-directed transfer and presystemic metabolism of selenoneine in a human intestinal barrier model. *Mol Nutr Food Res* **63**, e1900080.
49. Klein M, Ouerdane L, Bueno M, *et al.* (2011) Identification in human urine and blood of a novel selenium metabolite, S-methylselenoneine, a potential biomarker of metabolization in mammals of the naturally occurring selenoneine, by HPLC coupled to electrospray hybrid linear ion trap-orbital ion trap MS. *Metallomics* **3**, 513–520.
50. Pluskal T, Ueno M & Yanagida M (2014) Genetic and metabolomic dissection of the ergothioneine and selenoneine biosynthetic pathway in the fission yeast, *S. pombe*, and construction of an overproduction system. *PLOS ONE* **9**, e97774.
51. Yamashita Y & Yamashita M (2010) Identification of a novel selenium-containing compound, selenoneine, as the predominant chemical form of organic selenium in the blood of bluefin tuna. *J Biol Chem* **285**, 18134–18138.
52. Yamashita Y, Yabu T & Yamashita M (2010) Discovery of the strong antioxidant selenoneine in tuna and selenium redox metabolism. *World J Biol Chem* **1**, 144–150.
53. O'Hagan S & Kell DB (2017) Analysis of drug-endogenous human metabolite similarities in terms of their maximum common substructures. *J Cheminform* **9**, 18.
54. O'Hagan S & Kell DB (2016) MetMaxStruct: a Tversky-similarity-based strategy for analysing the (sub)structural similarities of drugs and endogenous metabolites. *Front Pharmacol* **7**, 266.
55. O'Hagan S & Kell DB (2015) The KNIME workflow environment and its applications in genetic programming and machine learning. *Genetic Progr Evol Mach* **16**, 387–391.
56. Thiele I, Swainston N, Fleming RMT, *et al.* (2013) A community-driven global reconstruction of human metabolism. *Nat Biotechnol* **31**, 419–425.
57. O'Hagan S, Swainston N, Handl J, *et al.* (2015) A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs. *Metabolomics* **11**, 323–339.
58. Lewis KA, Tzilivakis J, Warner DJ, *et al.* (2016) An international database for pesticide risk assessments and management. *Hum Ecol Risk Assess* **22**, 1050–1064.
59. Melville DB, Genghof DS, Inamine E, *et al.* (1956) Ergothioneine in microorganisms. *J Biol Chem* **223**, 9–17.
60. Jones GW, Doyle S & Fitzpatrick DA (2014) The evolutionary history of the genes involved in the biosynthesis of the antioxidant ergothioneine. *Gene* **549**, 161–170.
61. Newton GL, Arnold K, Price MS, *et al.* (1996) Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes. *J Bacteriol* **178**, 1990–1995.
62. Dosanjh M, Newton GL & Davies J (2008) Characterization of a mycothiol ligase mutant of *Rhodococcus jostii* RHA1. *Res Microbiol* **159**, 643–650.
63. Genghof DS & Van Damme O (1964) Biosynthesis of ergothioneine and hercynine by mycobacteria. *J Bacteriol* **87**, 852–862.
64. Genghof DS & Van Damme O (1968) Biosynthesis of ergothioneine from endogenous hercynine in *Mycobacterium smegmatis*. *J Bacteriol* **95**, 340–344.
65. Genghof DS (1970) Biosynthesis of ergothioneine and hercynine by fungi and Actinomycetales. *J Bacteriol* **103**, 475–478.
66. Trivedi A, Singh N, Bhat SA, *et al.* (2012) Redox biology of tuberculosis pathogenesis. *Adv Microb Physiol* **60**, 263–324.
67. Narainsamy K, Farci S, Braun E, *et al.* (2016) Oxidative-stress detoxification and signalling in cyanobacteria: the crucial glutathione synthesis pathway supports the production of ergothioneine and ophthalmate. *Mol Microbiol* **100**, 15–24.
68. Baran R, Bowen BP, Price MN, *et al.* (2013) Metabolic footprinting of mutant libraries to map metabolite utilization to genotype. *ACS Chem Biol* **8**, 189–199.
69. Baran R, Ivanova NN, Jose N, *et al.* (2013) Functional genomics of novel secondary metabolites from diverse cyanobacteria using untargeted metabolomics. *Mar Drugs* **11**, 3617–3631.
70. Pfeiffer C, Bauer T, Surek B, *et al.* (2011) Cyanobacteria produce high levels of ergothioneine. *Food Chem* **129**, 1766–1769.
71. Liao C & Seebeck FP (2017) Convergent evolution of ergothioneine biosynthesis in cyanobacteria. *Chembiochemistry* **18**, 2115–2118.
72. Alamgir KM, Masuda S, Fujitani Y, *et al.* (2015) Production of ergothioneine by *Methylobacterium* species. *Front Microbiol* **6**, 1185.
73. Rawat M & Av-Gay Y (2007) Mycothiol-dependent proteins in actinomycetes. *FEMS Microbiol Rev* **31**, 278–292.
74. Melville DB & Eich S (1956) The occurrence of ergothioneine in plant material. *J Biol Chem* **218**, 647–651.
75. Baran R, Brodie EL, Mayberry-Lewis J, *et al.* (2015) Exometabolite niche partitioning among sympatric soil bacteria. *Nat Commun* **6**, 8289.
76. Melville DB (1959) Ergothioneine. *Vitam Horm* **17**, 155–204.
77. Tan CH & Audley BG (1968) Ergothioneine and hercynine in *Hevea brasiliensis* latex. *Phytochemistry* **7**, 109–118.
78. Audley BG & Tan CH (1968) Uptake of ergothioneine from soil into latex of *Hevea brasiliensis*. *Phytochemistry* **7**, 1999–2000.
79. Warren CR (2013) Quaternary ammonium compounds can be abundant in some soils and are taken up as intact molecules by plants. *New Phytol* **198**, 476–485.
80. Park EJ, Lee WY, Kim ST, *et al.* (2010) Ergothioneine accumulation in a medicinal plant *Gastrodia elata*. *J Med Lant Res* **4**, 1141–1147.
81. Guo QL, Lin S, Wang YN, *et al.* (2016) Gastrolatathioneine, an unusual ergothioneine derivative from an aqueous extract of "tian ma": a natural product co-produced by plant and symbiotic fungus. *Chin Chem Lett* **27**, 1577–1581.
82. Melville DB, Otken CC & Kovalenko V (1955) On the origin of animal ergothioneine. *J Biol Chem* **216**, 325–331.
83. Melville DB, Horner WH, Otken CC, *et al.* (1955) Studies on the origin of ergothioneine in animals. *J Biol Chem* **213**, 61–68.
84. Eagles BA & Vars HM (1928) The physiology of ergothioneine. *J Biol Chem* **80**, 615–622.
85. Melville DB, Horner WH & Lubschez R (1954) Tissue ergothioneine. *J Biol Chem* **206**, 221–228.
86. Kawano H, Otani M, Takeyama K, *et al.* (1982) Studies on ergothioneine. VI. Distribution and fluctuations of ergothioneine in rats. *Chem Pharm Bull (Tokyo)* **30**, 1760–1765.
87. Tucker RAJ, Cheah IK & Halliwell B (2019) Specificity of the ergothioneine transporter natively expressed in HeLa cells. *Biochem Biophys Res Commun* **513**, 22–27.

88. Bu'Lock JD (1961) Intermediary metabolism and antibiotic synthesis. *Adv Microbial Physiol* **3**, 293–333.
89. Melville DB, Eich S & Ludwig ML (1957) The biosynthesis of ergothioneine. *J Biol Chem* **224**, 871–877.
90. Askari A & Melville DB (1962) The reaction sequence in ergothioneine biosynthesis: hercynine as an intermediate. *J Biol Chem* **237**, 1615–1618.
91. Seebeck FP (2013) Thiohistidine biosynthesis. *Chimia (Aarau)* **67**, 333–336.
92. Seebeck FP (2010) *In vitro* reconstitution of mycobacterial ergothioneine biosynthesis. *J Am Chem Soc* **132**, 6632–6633.
93. Richard-Greenblatt M, Bach H, Adamson J, *et al.* (2015) Regulation of ergothioneine biosynthesis and its effect on *Mycobacterium tuberculosis* growth and infectivity. *J Biol Chem* **290**, 23064–23076.
94. Naowarajana N, Cheng R, Chen L, *et al.* (2018) Mini-review: ergothioneine and oththiol biosyntheses, an unprecedented trans-sulfur strategy in natural product biosynthesis. *Biochemistry* **57**, 3309–3325.
95. Reinhold VN, Ishikawa Y & Melville DB (1970) Conversion of histidine to hercynine by *Neurospora crassa*. *J Bacteriol* **101**, 881–884.
96. Melville DB, Ludwig ML, Inamine E, *et al.* (1959) Transmethylation in the biosynthesis of ergothioneine. *J Biol Chem* **234**, 1195–1198.
97. Ishikawa Y, Israel SE & Melville DB (1974) Participation of an intermediate sulfoxide in the enzymatic thiolation of the imidazole ring of hercynine to form ergothioneine. *J Biol Chem* **249**, 4420–4427.
98. Leisinger F, Burn R, Meury M, *et al.* (2019) Structural and mechanistic basis for anaerobic ergothioneine biosynthesis. *J Am Chem Soc* **141**, 6906–6914.
99. Burn R, Misson L, Meury M, *et al.* (2017) Anaerobic origin of ergothioneine. *Angew Chem Int Ed Engl* **56**, 12508–12511.
100. Ruzsyczky MW & Liu HW (2017) The surprising history of an antioxidant. *Nature* **551**, 37–38.
101. Goncharenko KV, Vit A, Blankenfeldt W, *et al.* (2015) Structure of the sulfoxide synthase EgtB from the ergothioneine biosynthetic pathway. *Angew Chem Int Ed Engl* **54**, 2821–2824.
102. Vit A, Mashabela GT, Blankenfeldt W, *et al.* (2015) Structure of the ergothioneine-biosynthesis amidohydrolase EgtC. *ChemBioChem* **16**, 1490–1496.
103. Vit A, Misson L, Blankenfeldt W, *et al.* (2014) Crystallization and preliminary X-ray analysis of the ergothioneine-biosynthetic methyltransferase EgtD. *Acta Crystallogr F Struct Biol Commun* **70**, 676–680.
104. Vit A, Misson L, Blankenfeldt W, *et al.* (2015) Ergothioneine biosynthetic methyltransferase EgtD reveals the structural basis of aromatic amino acid betaine biosynthesis. *ChemBioChem* **16**, 119–125.
105. Misson L, Burn R, Vit A, *et al.* (2018) Inhibition and regulation of the ergothioneine biosynthetic methyltransferase EgtD. *ACS Chem Biol* **13**, 1333–1342.
106. Irani S, Naowarajana N, Tang Y, *et al.* (2018) Snapshots of C-S cleavage in Egt2 reveals substrate specificity and reaction mechanism. *Cell Chem Biol* **25**, 519–529.e514.
107. Naowarajana N, Irani S, Hu WY, *et al.* (2019) Crystal structure of the ergothioneine sulfoxide synthase from *Candidatus Chloracidobacterium thermophilum* and structure-guided engineering to modulate its substrate selectivity. *ACS Catal* **9**, 6955–6961.
108. Uniprot (2019) *Neurospora crassa* EGT1. <https://www.uniprot.org/uniprot/Q7RX33> (accessed August 2019).
109. Uniprot (2019) *Mycobacterium tuberculosis* EGTD. <https://www.uniprot.org/uniprot/P9WN46> (accessed August 2019).
110. Daunay S, Lebel R, Farescour L, *et al.* (2016) Short protecting-group-free synthesis of 5-acetylsulfanyl-histidines in water: novel precursors of 5-sulfanyl-histidine and its analogues. *Org Biomol Chem* **14**, 10473–10480.
111. Xu JZ & Yadan JC (1995) Synthesis of 1-(+)-ergothioneine. *J Org Chem* **60**, 6296–6301.
112. Khonde PL & Jardine A (2015) Improved synthesis of the super antioxidant, ergothioneine, and its biosynthetic pathway intermediates. *Org Biomol Chem* **13**, 1415–1419.
113. Fujitani Y, Alamgir KM & Tani A (2018) Ergothioneine production using *Methylobacterium* species, yeast, and fungi. *J Biosci Bioeng* **126**, 715–722.
114. Takusagawa S, Satoh Y, Ohtsu I, *et al.* (2019) Ergothioneine production with *Aspergillus oryzae*. *Biosci Biotechnol Biochem* **83**, 181–184.
115. Osawa R, Kamide T, Satoh Y, *et al.* (2018) Heterologous and high production of ergothioneine in *Escherichia coli*. *J Agric Food Chem* **66**, 1191–1196.
116. Tanaka N, Kawano Y, Satoh Y, *et al.* (2019) Gram-scale fermentative production of ergothioneine driven by overproduction of cysteine in *Escherichia coli*. *Sci Rep* **9**, 1895.
117. van der Hoek SA, Darbani B, Zugaj K, *et al.* (2019) Engineering the yeast *Saccharomyces cerevisiae* for the production of 1-(+)-ergothioneine. *Front Bioeng Biotechnol* **7**, 262.
118. Li M & Borodina I (2015) Application of synthetic biology for production of chemicals in yeast *Saccharomyces cerevisiae*. *FEMS Yeast Res* **15**, 1–12.
119. O'Hagan S, Wright Muelas M, Day PJ, *et al.* (2018) GeneGini: assessment via the Gini coefficient of reference “housekeeping” genes and diverse human transporter expression profiles. *Cell Syst* **6**, 230–244.
120. Chaleckis R, Ebe M, Pluskal T, *et al.* (2014) Unexpected similarities between the *Schizosaccharomyces* and human blood metabolomes, and novel human metabolites. *Mol Biosyst* **10**, 2538–2551.
121. McMenamy RH, Lund CC & Wallach DF (1960) Unbound amino acid concentrations in plasma, erythrocytes and urine of patients with leukemia. *J Clin Invest* **39**, 1688–1705.
122. McMenamy RH, Lund CC, Neville GJ, *et al.* (1960) Studies of unbound amino acid distributions in plasma, erythrocytes, leukocytes and urine of normal human subjects. *J Clin Invest* **39**, 1675–1687.
123. Arduini A, Mancinelli G, Radatti GL, *et al.* (1992) Possible mechanism of inhibition of nitrite-induced oxidation of oxyhemoglobin by ergothioneine and uric acid. *Arch Biochem Biophys* **294**, 398–402.
124. Li RWS, Yang C, Sit ASM, *et al.* (2014) Uptake and protective effects of ergothioneine in human endothelial cells. *J Pharmacol Exp Ther* **350**, 691–700.
125. Weigand-Heller AJ, Kris-Etherton PM & Beelman RB (2012) The bioavailability of ergothioneine from mushrooms (*Agaricus bisporus*) and the acute effects on antioxidant capacity and biomarkers of inflammation. *Prev Med* **54**, Suppl., S75–S78.
126. Reglinski J, Smith WE, Wilson R, *et al.* (1991) Clinical analysis in intact erythrocytes using ¹H spin echo NMR. *Clin Chim Acta* **201**, 45–57.
127. Wang LZ, Thuya WL, Toh DS, *et al.* (2013) Quantification of 1-ergothioneine in human plasma and erythrocytes by liquid chromatography–tandem mass spectrometry. *J Mass Spectrom* **48**, 406–412.
128. Turner E, Brewster JA, Simpson NA, *et al.* (2009) Imidazole-based erythrocyte markers of oxidative stress in pre-eclampsia – an NMR investigation. *Reprod Sci* **16**, 1040–1051.

129. Mitsuyama H & May JM (1999) Uptake and antioxidant effects of ergothioneine in human erythrocytes. *Clin Sci (Lond)* **97**, 407–411.
130. Gründemann D, Harlfinger S, Golz S, *et al.* (2005) Discovery of the ergothioneine transporter. *Proc Natl Acad Sci U S A* **102**, 5256–5261.
131. Tang RMY, Cheah IK, Yew TSK, *et al.* (2018) Distribution and accumulation of dietary ergothioneine and its metabolites in mouse tissues. *Sci Rep* **8**, 1601.
132. Nikodemus D, Lazic D, Bach M, *et al.* (2011) Paramount levels of ergothioneine transporter SLC22A4 mRNA in boar seminal vesicles and cross-species analysis of ergothioneine and glutathione in seminal plasma. *J Physiol Pharmacol* **62**, 411–419.
133. Kaneko I, Takeuchi Y, Yamaoka Y, *et al.* (1980) Quantitative determination of ergothioneine in plasma and tissues by TLC-densitometry. *Chem Pharm Bull (Tokyo)* **28**, 3093–3097.
134. Shires TK, Brummel MC, Pulido JS, *et al.* (1997) Ergothioneine distribution in bovine and porcine ocular tissues. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol* **117**, 117–120.
135. Crossland J, Mitchell J & Woodruff GN (1966) The presence of ergothioneine in the central nervous system and its probable identity with the cerebellar factor. *J Physiol* **182**, 427–438.
136. Nakamichi N, Taguchi T, Hosotani H, *et al.* (2012) Functional expression of carnitine/organic cation transporter OCTN1 in mouse brain neurons: possible involvement in neuronal differentiation. *Neurochem Int* **61**, 1121–1132.
137. Vermeulen E & Vermeersch P (2012) Hepcidin as a biomarker for the diagnosis of iron metabolism disorders: a review. *Acta Clin Belg* **67**, 190–197.
138. Ganz T & Nemeth E (2011) The hepcidin–ferroportin system as a therapeutic target in anemias and iron overload disorders. *Hematol Am Soc Hematol Educ Program* **2011**, 538–542.
139. Ganz T & Nemeth E (2012) Hepcidin and iron homeostasis. *Biochim Biophys Acta* **1823**, 1434–1443.
140. Nemeth E & Ganz T (2009) The role of hepcidin in iron metabolism. *Acta Haematol* **122**, 78–86.
141. Reichert CO, da Cunha J, Levy D, *et al.* (2017) Hepcidin: homeostasis and diseases related to iron metabolism. *Acta Haematol* **137**, 220–236.
142. Kell DB, Swainston N, Pir P, *et al.* (2015) Membrane transporter engineering in industrial biotechnology and whole-cell biocatalysis. *Trends Biotechnol* **33**, 237–246.
143. Dobson PD & Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? *Nat Rev Drug Disc* **7**, 205–220.
144. Kell DB & Dobson PD (2009) The cellular uptake of pharmaceutical drugs is mainly carrier-mediated and is thus an issue not so much of biophysics but of systems biology. In *Proceedings of the International Beilstein Symposium on Systems Chemistry*, pp. 149–168 [MG Hicks and C Kettner, editors]. Berlin: Logos Verlag.
145. Kell DB, Dobson PD & Oliver SG (2011) Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. *Drug Disc Today* **16**, 704–714.
146. Kell DB, Dobson PD, Bilsland E, *et al.* (2013) The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. *Drug Disc Today* **18**, 218–239.
147. Kell DB (2013) Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening, and knowledge of transporters: where drug discovery went wrong and how to fix it. *FEBS J* **280**, 5957–5980.
148. Kell DB & Oliver SG (2014) How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. *Front Pharmacol* **5**, 231.
149. Kell DB (2015) The transporter-mediated cellular uptake of pharmaceutical drugs is based on their metabolite-likeness and not on their bulk biophysical properties: towards a systems pharmacology. *Perspect Sci* **6**, 66–83.
150. Kell DB (2016) How drugs pass through biological cell membranes – a paradigm shift in our understanding? *Beilstein Magazine* **2**, no. 5.
151. Giacomini KM, Huang SM, Tweedie DJ, *et al.* (2010) Membrane transporters in drug development. *Nat Rev Drug Discov* **9**, 215–236.
152. Dickens D, Rädisch S, Chiduzza GN, *et al.* (2018) Cellular uptake of the atypical antipsychotic clozapine is a carrier-mediated process. *Mol Pharm* **15**, 3557–3572.
153. César-Razquin A, Snijder B, Frappier-Brinton T, *et al.* (2015) A call for systematic research on solute carriers. *Cell* **162**, 478–487.
154. Hediger MA, Clemençon B, Burrier RE, *et al.* (2013) The ABCs of membrane transporters in health and disease (SLC series): Introduction. *Mol Aspects Med* **34**, 95–107.
155. Anonymous (2019) SLC Tables. <http://www.bioparadigms.org/slc/intro.htm> (accessed August 2019)
156. Chen Z, Shi T, Zhang L, *et al.* (2016) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multi-drug resistance: a review of the past decade. *Cancer Lett* **370**, 153–164.
157. Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. *Mol Aspects Med* **34**, 413–435.
158. Pochini L, Galluccio M, Scalise M, *et al.* (2019) OCTN: a small transporter subfamily with great relevance to human pathophysiology, drug discovery, and diagnostics. *SLAS Discov* **24**, 89–110.
159. Garg N, Kapon C, Lim YW, *et al.* (2015) Mass spectral similarity for untargeted metabolomics data analysis of complex mixtures. *Int J Mass Spectrom* **377**, 719–717.
160. Li XS, Wang Z, Cajka T, *et al.* (2018) Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. *JCI Insight* **3**, 99096.
161. Coene KLM, Kluijtmans LAJ, van der Heeft E, *et al.* (2018) Next-generation metabolic screening: targeted and untargeted metabolomics for the diagnosis of inborn errors of metabolism in individual patients. *J Inher Metab Dis* **41**, 337–353.
162. Tautenhahn R, Cho K, Uritboonthai W, *et al.* (2012) An accelerated workflow for untargeted metabolomics using the METLIN database. *Nature Biotechnol* **30**, 826–828.
163. Dunn WB, Broadhurst D, Begley P, *et al.* (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nat Protoc* **6**, 1060–1083.
164. Dunn WB, Erban A, Weber RJM, *et al.* (2013) Mass appeal: metabolite identification in mass spectrometry-focused untargeted metabolomics. *Metabolomics* **9**, Suppl. 1, S44–S66.
165. Heinzmann SS, Brown IJ, Chan Q, *et al.* (2010) Metabolic profiling strategy for discovery of nutritional biomarkers: proline betaine as a marker of citrus consumption. *Am J Clin Nutr* **92**, 436–443.
166. Lang R, Lang T, Bader M, *et al.* (2017) High-throughput quantitation of proline betaine in foods and suitability as a valid biomarker for citrus consumption. *J Agric Food Chem* **65**, 1613–1619.
167. Lloyd AJ, Beckmann M, Favé G, *et al.* (2011) Proline betaine and its biotransformation products in fasting urine samples

- are potential biomarkers of habitual citrus fruit consumption. *Br J Nutr* **106**, 812–824.
168. Gasteiger J (2003) *Basic Chemoinformatics: A Textbook*. Weinheim: Wiley/VCH.
 169. Bacher P, Giersiefer S, Bach M, *et al.* (2009) Substrate discrimination by ergothioneine transporter SLC22A4 and carnitine transporter SLC22A5: gain-of-function by interchange of selected amino acids. *Biochim Biophys Acta* **1788**, 2594–2602.
 170. Grigat S, Harlfinger S, Pal S, *et al.* (2007) Probing the substrate specificity of the ergothioneine transporter with methimazole, mercynine, and organic cations. *Biochem Pharmacol* **74**, 309–316.
 171. Gründemann D (2012) The ergothioneine transporter controls and indicates ergothioneine activity – a review. *Prev Med* **54**, Suppl., S71–S74.
 172. Tschirka J, Kreisor M, Betz J, *et al.* (2018) Substrate selectivity check of the ergothioneine transporter. *Drug Metab Dispos* **46**, 779–785.
 173. Shimizu T, Masuo Y, Takahashi S, *et al.* (2015) Organic cation transporter OCTN1-mediated uptake of food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation in mice. *Drug Metab Pharmacokin* **30**, 231–239.
 174. Yabuuchi H, Tamai I, Nezu J, *et al.* (1999) Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. *J Pharmacol Exp Ther* **289**, 768–773.
 175. Akamine T, Koyanagi S, Kusunose N, *et al.* (2015) Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice. *J Pharmacol Exp Ther* **354**, 65–72.
 176. Shimizu T, Kijima A, Masuo Y, *et al.* (2015) Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice. *Biol Pharm Bull* **38**, 774–780.
 177. Tamai I (2013) Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). *Biopharm Drug Dispos* **34**, 29–44.
 178. Nakamura T, Yoshida K, Yabuuchi H, *et al.* (2008) Functional characterization of ergothioneine transport by rat organic cation/carnitine transporter OCTN1 (SLC22A4). *Biol Pharm Bull* **31**, 1580–1584.
 179. Darghouth D, Giarratana MC, Oliveira L, *et al.* (2016) Bio-engineered and native red blood cells from cord blood exhibit the same metabolomic profile. *Haematologica* **101**, e220–e222.
 180. Taubert D, Lazar A, Grimberg G, *et al.* (2006) Association of rheumatoid arthritis with ergothioneine levels in red blood cells: a case control study. *J Rheumatol* **33**, 2139–2145.
 181. Indiveri C, Galluccio M, Scalise M, *et al.* (2013) Strategies of bacterial over expression of membrane transporters relevant in human health: the successful case of the three members of OCTN subfamily. *Mol Biotechnol* **54**, 724–736.
 182. Frigeni M, Iacobazzi F, Yin X, *et al.* (2016) Wide tolerance to amino acids substitutions in the OCTN1 ergothioneine transporter. *Biochim Biophys Acta* **1860**, 1334–1342.
 183. Nigam SK (2018) The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. *Annu Rev Pharmacol Toxicol* **58**, 663–687.
 184. Pochini L, Scalise M, Galluccio M, *et al.* (2013) OCTN cation transporters in health and disease: role as drug targets and assay development. *J Biomol Screen* **18**, 851–867.
 185. Wolf KK & Paine MF (2018) Metabolic barrier of the gastrointestinal tract. In *Comprehensive Toxicology*, 3rd ed., pp. 74–98 [C McQueen, editor]. Amsterdam: Elsevier.
 186. Thul PJ, Åkesson L, Wiking M, *et al.* (2017) A subcellular map of the human proteome. *Science* **356**, eaal3321.
 187. Apostolova N & Victor VM (2015) Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications. *Antioxid Redox Signal* **22**, 686–729.
 188. Lamhonwah AM & Tein I (2006) Novel localization of OCTN1, an organic cation/carnitine transporter, to mammalian mitochondria. *Biochem Biophys Res Commun* **345**, 1315–1325.
 189. Lamhonwah AM, Hawkins CE, Tam C, *et al.* (2008) Expression patterns of the organic cation/carnitine transporter family in adult murine brain. *Brain Dev* **30**, 31–42.
 190. Xuan W, Lamhonwah AM, Librach C, *et al.* (2003) Characterization of organic cation/carnitine transporter family in human sperm. *Biochem Biophys Res Commun* **306**, 121–128.
 191. Anonymous (2019) SLC22A4. <https://www.proteinatlas.org/ENSG00000197208-SLC22A4/cell> (accessed August 2019).
 192. Skogs M, Stadler C, Schutten R, *et al.* (2017) Antibody validation in bioimaging applications based on endogenous expression of tagged proteins. *J Proteome Res* **16**, 147–155.
 193. Edfors F, Hober A, Linderbäck K, *et al.* (2018) Enhanced validation of antibodies for research applications. *Nat Commun* **9**, 4130.
 194. Rabia LA, Desai AA, Jhaji HS, *et al.* (2018) Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. *Biochem Eng J* **137**, 365–374.
 195. Jain D & Salunke DM (2019) Antibody specificity and promiscuity. *Biochem J* **476**, 433–447.
 196. Edwards BM, Barash SC, Main SH, *et al.* (2003) The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BlyS. *J Mol Biol* **334**, 103–118.
 197. Vaughan TJ, Osbourn JK & Tempest PR (1998) Human antibodies by design. *Nat Biotechnol* **16**, 535–539.
 198. Michaud GA, Salcius M, Zhou F, *et al.* (2003) Analyzing antibody specificity with whole proteome microarrays. *Nat Biotechnol* **21**, 1509–1512.
 199. Palmieri F (2013) The mitochondrial transporter family SLC25: identification, properties and physiopathology. *Mol Aspects Med* **34**, 465–484.
 200. Palmieri F (2014) Mitochondrial transporters of the SLC25 family and associated diseases: a review. *J Inherit Metab Dis* **37**, 565–575.
 201. Anonymous (2019) Q9H015 tree in phylome 533. http://phylomedb.org/?q=search_tree&seqid=Q9H015# (accessed August 2019).
 202. Anonymous (2019) GeneTree Image. <http://www.ensembl.org/Multi/GeneTree/Image?gt=ENSGT00940000154155> (accessed August 2019).
 203. O'Hagan S & Kell DB (2017) Consensus rank orderings of molecular fingerprints illustrate the 'most genuine' similarities between marketed drugs and small endogenous human metabolites, but highlight exogenous natural products as the most important 'natural' drug transporter substrates. *ADMET DMPK* **5**, 85–125.
 204. Chapy H, Smirnova M, Andre P, *et al.* (2014) Carrier-mediated cocaine transport at the blood–brain barrier as a putative mechanism in addiction liability. *Int J Neuropsychopharmacol* **18**, pyu001.
 205. Danchin A (2018) Bacteria in the ageing gut: did the taming of fire promote a long human lifespan? *Environ Microbiol* **20**, 1966–1987.

206. Kell DB & Pretorius E (2018) No effects without causes. The iron dysregulation and dormant microbes hypothesis for chronic, inflammatory diseases. *Biol Rev* **93**, 1518–1557.
207. Butterfield DA & Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. *Nat Rev Neurosci* **20**, 148–160.
208. Kell DB (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. *BMC Med Genomics* **2**, 2.
209. Babior BM (2000) Phagocytes and oxidative stress. *Am J Med* **109**, 33–44.
210. Cave AC, Brewer AC, Narayanapanicker A, *et al.* (2006) NADPH oxidases in cardiovascular health and disease. *Antioxid Redox Signal* **8**, 691–728.
211. Bedard K & Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiol Rev* **87**, 245–313.
212. Wardman P & Candeias LP (1996) Fenton chemistry: an introduction. *Rad Res* **145**, 523–531.
213. Kell DB (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. *Arch Toxicol* **577**, 825–889.
214. Winston GW, Feerman DE & Cederbaum AI (1984) The role of iron chelates in hydroxyl radical production by rat liver microsomes, NADPH-cytochrome P-450 reductase and xanthine oxidase. *Arch Biochem Biophys* **232**, 378–390.
215. Fong A & Hieftje GM (1995) Near-IR multiplex bandpass spectrometer utilizing liquid molecular filters. *Appl Spectrosc* **49**, 493–498.
216. Kehrer JP (2000) The Haber–Weiss reaction and mechanisms of toxicity. *Toxicology* **149**, 43–50.
217. Kell DB & Pretorius E (2014) Serum ferritin is an important disease marker, and is mainly a leakage product from damaged cells. *Metallomics* **6**, 748–773.
218. Valachová K, Mach M, Dubovický M, *et al.* (2019) The importance of ergothioneine synthesis in ancient time by organisms living in oxygen free atmosphere. *Med Hypotheses* **123**, 72–73.
219. Migliore L, Fontana I, Colognato R, *et al.* (2005) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. *Neurobiol Aging* **26**, 587–595.
220. Ahsan H (2013) 3-Nitrotyrosine: a biomarker of nitrogen free radical species modified proteins in systemic autoimmune-genic conditions. *Hum Immunol* **74**, 1392–1399.
221. Bartesaghi S & Radi R (2018) Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration. *Redox Biol* **14**, 618–625.
222. Ryberg H & Caidahl K (2007) Chromatographic and mass spectrometric methods for quantitative determination of 3-nitrotyrosine in biological samples and their application to human samples. *J Chromatogr B* **851**, 160–171.
223. Rahman I (2012) Pharmacological antioxidant strategies as therapeutic interventions for COPD. *Biochim Biophys Acta* **1822**, 714–728.
224. Aruoma OI, Whiteman M, England TG, *et al.* (1997) Antioxidant action of ergothioneine: assessment of its ability to scavenge peroxynitrite. *Biochem Biophys Res Commun* **231**, 389–391.
225. Halliwell B (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation *in vivo*? *FEBS Lett* **411**, 157–160.
226. Ferrer-Sueta G, Campolo N, Trujillo M, *et al.* (2018) Biochemistry of peroxynitrite and protein tyrosine nitration. *Chem Rev* **118**, 1338–1408.
227. Petersen DR & Doorn JA (2004) Reactions of 4-hydroxynonenal with proteins and cellular targets. *Free Radic Biol Med* **37**, 937–945.
228. Akanmu D, Cecchini R, Aruoma OI, *et al.* (1991) The antioxidant action of ergothioneine. *Arch Biochem Biophys* **288**, 10–16.
229. Asmus KD, Bensasson RV, Bernier JL, *et al.* (1996) One-electron oxidation of ergothioneine and analogues investigated by pulse radiolysis: redox reaction involving ergothioneine and vitamin C. *Biochem J* **315**, 625–629.
230. Motohashi N & Mori I (1986) Thiol-induced hydroxyl radical formation and scavenger effect of thiocarbamides on hydroxyl radicals. *J Inorg Biochem* **26**, 205–212.
231. Jang JH, Aruoma OI, Jen LS, *et al.* (2004) Ergothioneine rescues PC12 cells from β -amyloid-induced apoptotic death. *Free Radic Biol Med* **36**, 288–299.
232. Chaudière J & Ferrari-Iliou R (1999) Intracellular antioxidants: from chemical to biochemical mechanisms. *Food Chem Toxicol* **37**, 949–962.
233. Oumari M, Goldfuss B, Stoffels C, *et al.* (2019) Regeneration of ergothioneine after reaction with singlet oxygen. *Free Radic Biol Med* **134**, 498–504.
234. Devasagayam TPA, Sundquist AR, Di Mascio P, *et al.* (1991) Activity of thiols as singlet molecular oxygen quenchers. *J Photochem Photobiol B* **9**, 105–116.
235. Hartman PE, Hartman Z & Ault KT (1990) Scavenging of singlet molecular oxygen by imidazole compounds: high and sustained activities of carboxy terminal histidine dipeptides and exceptional activity of imidazole-4-acetic acid. *Photochem Photobiol* **51**, 59–66.
236. van den Broeke LT & Beyersbergen van Henegouwen GM (1993) Thiols as potential UV radiation protectors: an *in vitro* study. *J Photochem Photobiol B* **17**, 279–286.
237. Egorov S, Kurella EG, Boldyrev AA, *et al.* (1997) Quenching of singlet molecular oxygen by carnosine and related antioxidants. Monitoring 1270-nm phosphorescence in aqueous media. *Biochem Mol Biol Int* **41**, 687–694.
238. Boldyrev A & Abe H (1999) Metabolic transformation of neuropeptide carnosine modifies its biological activity. *Cell Mol Neurobiol* **19**, 163–175.
239. Dahl TA, Midden WR & Hartman PE (1988) Some prevalent biomolecules as defenses against singlet oxygen damage. *Photochem Photobiol* **47**, 357–362.
240. Dong KK, Damaghi N, Kibitil J, *et al.* (2007) A comparison of the relative antioxidant potency of L-ergothioneine and idebenone. *J Cosmet Dermatol* **6**, 183–188.
241. Obayashi K, Kurihara K, Okano Y, *et al.* (2005) L-Ergothioneine scavenges superoxide and singlet oxygen and suppresses TNF- α and MMP-1 expression in UV-irradiated human dermal fibroblasts. *J Cosmet Sci* **56**, 17–27.
242. Stoffels C, Oumari M, Perrou A, *et al.* (2017) Ergothioneine stands out from hercynine in the reaction with singlet oxygen: resistance to glutathione and TRIS in the generation of specific products indicates high reactivity. *Free Radic Biol Med* **113**, 385–394.
243. He QC, Krone K, Scherl D, *et al.* (2004) The use of ozone as an oxidizing agent to evaluate antioxidant activities of natural substrates. *Skin Pharmacol Physiol* **17**, 183–189.
244. Markova NG, Karaman-Jurukovska N, Dong KK, *et al.* (2009) Skin cells and tissue are capable of using L-ergothioneine as an integral component of their antioxidant defense system. *Free Radic Biol Med* **46**, 1168–1176.

245. Nguyen TH, Nagasaka R & Ohshima T (2013) The natural antioxidant ergothioneine: resources, chemical characterization, and applications. In *Lipid Oxidation: Challenges in Food Systems*, pp. 381–415 [A Logan, U Nienaber and X Pan, editors]. Urbana, IL: AOCS Press.
246. Servillo L, D'Onofrio N, Casale R, *et al.* (2017) Ergothioneine products derived by superoxide oxidation in endothelial cells exposed to high-glucose. *Free Radic Biol Med* **108**, 8–18.
247. Bello MH, Barrera-Perez V, Morin D, *et al.* (2012) The *Neurospora crassa* mutant *NcΔEgt-1* identifies an ergothioneine biosynthetic gene and demonstrates that ergothioneine enhances conidial survival and protects against peroxide toxicity during conidial germination. *Fungal Genet Biol* **49**, 160–172.
248. Hartman PE (1990) Ergothioneine as antioxidant. *Meth Enzymol* **186**, 310–318.
249. Asahi T, Wu X, Shimoda H, *et al.* (2016) A mushroom-derived amino acid, ergothioneine, is a potential inhibitor of inflammation-related DNA halogenation. *Biosci Biotechnol Biochem* **80**, 313–317.
250. Whiteman M & Halliwell B (1997) Thiols and disulphides can aggravate peroxynitrite-dependent inactivation of α 1-antiproteinase. *FEBS Lett* **414**, 497–500.
251. Aruoma OI, Spencer JPE & Mahmood N (1999) Protection against oxidative damage and cell death by the natural antioxidant ergothioneine. *Food Chem Toxicol* **37**, 1043–1053.
252. Garay AS (1956) On the effect of some protective and stimulatory substances in honey-dew on the germination of ergot conidia. *Physiol Plantarum* **9**, 344–349.
253. Garay AS (1956) Role of ergothioneine and catalase in infection by ergot fungus (*Claviceps purpurea* Tul.). *Nature* **177**, 91–92.
254. Sao Emani C, Williams MJ, Wiid IJ, *et al.* (2013) Ergothioneine is a secreted antioxidant in *Mycobacterium smegmatis*. *Antimicrob Agents Chemother* **57**, 3202–3207.
255. Nakajima S, Satoh Y, Yanashima K, *et al.* (2015) Ergothioneine protects *Streptomyces coelicolor* A3(2) from oxidative stresses. *J Biosci Bioeng* **120**, 294–298.
256. Liu H, Zhao X, Guo M, *et al.* (2015) Growth and metabolism of *Beauveria bassiana* spores and mycelia. *BMC Microbiol* **15**, 267.
257. Sheridan KJ, Lechner BE, Keeffe GO, *et al.* (2016) Ergothioneine biosynthesis and functionality in the opportunistic fungal pathogen, *Aspergillus fumigatus*. *Sci Rep* **6**, 35306.
258. Ta P, Buchmeier N, Newton GL, *et al.* (2011) Organic hydroperoxide resistance protein and ergothioneine compensate for loss of mycothiol in *Mycobacterium smegmatis* mutants. *J Bacteriol* **193**, 1981–1990.
259. Cumming BM, Lamprecht DA, Wells RM, *et al.* (2014) The physiology and genetics of oxidative stress in mycobacteria. *Microbiol Spectr* **2** (epublication 2 May 2014).
260. Cumming BM, Chinta KC, Reddy VP, *et al.* (2018) Role of ergothioneine in microbial physiology and pathogenesis. *Antioxid Redox Signal* **28**, 431–444.
261. Farhana A, Guidry L, Srivastava A, *et al.* (2010) Reductive stress in microbes: implications for understanding *Mycobacterium tuberculosis* disease and persistence. *Adv Microb Physiol* **57**, 43–117.
262. Kurutas EB (2016) The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state. *Nutr J* **15**, 71.
263. Cardoso SM (2019) Special issue: the antioxidant capacities of natural products. *Molecules* **24**, 492–495.
264. Ooi BK, Chan K-G, Goh BH, *et al.* (2018) The role of natural products in targeting cardiovascular diseases via Nrf2 pathway: novel molecular mechanisms and therapeutic approaches. *Front Pharmacol* **9**, 1308.
265. Urquiaga I & Leighton F (2000) Plant polyphenol antioxidants and oxidative stress. *Biol Res* **33**, 55–64.
266. Chen W, Jia Z, Pan MH, *et al.* (2016) Natural products for the prevention of oxidative stress-related diseases: mechanisms and strategies. *Oxid Med Cell Longev* **2016**, 4628502.
267. Salehi B, Stojanović-Radić Z, Matejić J, *et al.* (2019) The therapeutic potential of curcumin: a review of clinical trials. *Eur J Med Chem* **163**, 527–545.
268. Gonçalves PB, Romeiro NC (2019) Multi-target natural products as alternatives against oxidative stress in chronic obstructive pulmonary disease (COPD). *Eur J Med Chem* **163**, 911–931.
269. Jia ZQ, Anandh Babu PV, Chen W, *et al.* (2018) Natural products targeting on oxidative stress and inflammation: mechanisms, therapies, and safety assessment. *Oxid Med Cell Longev* **2018**, 6576093.
270. Davey HM & Kell DB (1996) Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analysis. *Microbiol Rev* **60**, 641–696.
271. Savoie J-M, Minvielle N & Largeteau ML (2008) Radical-scavenging properties of extracts from the white button mushroom, *Agaricus bisporus*. *J Sci Food Agric* **88**, 870–875.
272. Yokota ME, Frison PS, Marcante RC, *et al.* (2016) Iron translocation in *Pleurotus ostreatus* basidiocarps: production, bio-availability, and antioxidant activity. *Genet Mol Res* **15**.
273. Kozarski M, Klaus A, Jakovljevic D, *et al.* (2015) Antioxidants of edible mushrooms. *Molecules* **20**, 19489–19525.
274. Zhao H, Zhang M, Liu Q, *et al.* (2018) A comprehensive screening shows that ergothioneine is the most abundant antioxidant in the wild macrofungus *Phylloporia ribis* Ryvarden. *J Environ Sci Health C* **36**, 98–111.
275. Dubost NJ, Ou B & Beelman RB (2007) Quantification of polyphenols and ergothioneine in cultivated mushrooms and correlation to total antioxidant capacity. *Food Chem* **105**, 727–735.
276. Liao WC, Wu WH, Tsai PC, *et al.* (2012) Kinetics of ergothioneine inhibition of mushroom tyrosinase. *Appl Biochem Biotechnol* **166**, 259–267.
277. Kell DB, Kaprelyants AS & Grafen A (1995) On pheromones, social behaviour and the functions of secondary metabolism in bacteria. *Trends Ecol Evolution* **10**, 126–129.
278. Gallagher L, Owens RA, Dolan SK, *et al.* (2012) The *Aspergillus fumigatus* protein GliK protects against oxidative stress and is essential for gliotoxin biosynthesis. *Eukaryot Cell* **11**, 1226–1238.
279. Song H, Her AS, Raso F, *et al.* (2014) Cysteine oxidation reactions catalyzed by a mononuclear non-heme iron enzyme (OvoA) in ovothiol biosynthesis. *Org Lett* **16**, 2122–2125.
280. Castellano I & Seebeck FP (2018) On ovothiol biosynthesis and biological roles: from life in the ocean to therapeutic potential. *Nat Prod Rep* **35**, 1241–1250.
281. Vázquez-Fresno R, Rosana ARR, Sajed T, *et al.* (2019) Herbs and spices- biomarkers of intake based on human intervention studies – a systematic review. *Genes Nutr* **14**, 18.
282. Menon VP & Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. *Adv Exp Med Biol* **595**, 105–125.
283. Abrahams S, Haylett WL, Johnson G, *et al.* (2019) Antioxidant effects of curcumin in models of neurodegeneration, aging, oxidative and nitrosative stress: a review. *Neuroscience* **406**, 1–21.
284. Li H, Sureda A, Devkota HP, *et al.* (2019) Curcumin, the golden spice in treating cardiovascular diseases. *Biotechnol*

- Adv* **2019**, S0734-9750(19)30010-2 (epublication ahead of print version 1 February 2019).
285. Sanei M & Saberi-Demneh A (2019) Effect of curcumin on memory impairment: a systematic review. *Phytomedicine* **52**, 98–106.
 286. Tomeh MA, Hadianamrei R & Zhao X (2019) A review of curcumin and its derivatives as anticancer agents. *Int J Mol Sci* **20**, E1033.
 287. Pekkinen J, Rosa-Sibakov N, Micard V, *et al.* (2015) Amino acid-derived betaines dominate as urinary markers for rye bran intake in mice fed high-fat diet – a nontargeted metabolomics study. *Mol Nutr Food Res* **59**, 1550–1562.
 288. Kempf B & Bremer E (1998) Uptake and synthesis of compatible solutes as microbial stress responses to high-osmolality environments. *Arch Microbiol* **170**, 319–330.
 289. Roberts MF (2005) Organic compatible solutes of halotolerant and halophilic microorganisms. *Saline Systems* **1**, 5.
 290. Wani SH, Singh NB, Haribhushan A, *et al.* (2013) Compatible solute engineering in plants for abiotic stress tolerance – role of glycine betaine. *Curr Genomics* **14**, 157–165.
 291. Weinand M, Krämer R, Morbach S (2007) Characterization of compatible solute transporter multiplicity in *Corynebacterium glutamicum*. *Appl Microbiol Biotechnol* **76**, 701–708.
 292. Imhoff JF & Rodriguez-Valera F (1984) Betaine is the main compatible solute of halophilic eubacteria. *Bacteriology* **160**, 478–479.
 293. Fahner B (2012) Using folding promoting agents in recombinant protein production: a review. *Methods Mol Biol* **824**, 3–36.
 294. Ey J, Schömig E & Taubert D (2007) Dietary sources and antioxidant effects of ergothioneine. *J Agric Food Chem* **55**, 6466–6474.
 295. Lee DP, Alexander D & Jonnalagadda SS (2013) Diversity of nutrient content in grains – a pilot metabolomics analysis. *J Nutr Food Sci* **3**, 10.4172/2155-9600.1000191.
 296. Wang Y, Gapstur SM, Carter BD, *et al.* (2018) Untargeted metabolomics identifies novel potential biomarkers of habitual food intake in a cross-sectional study of postmenopausal women. *J Nutr* **148**, 932–943.
 297. Pallister T, Jennings A, Mohny RP, *et al.* (2016) Characterizing blood metabolomics profiles associated with self-reported food intakes in female twins. *PLOS ONE* **11**, e0158568.
 298. Dubost NJ, Beelman RB, Peterson D, *et al.* (2005) Identification and quantification of ergothioneine in cultivated mushrooms by liquid chromatography–mass spectroscopy. *Int J Med Mush* **8**, 215–222.
 299. Dubost NJ, Beelman RB & Royse DJ (2007) Influence of selected cultural factors and postharvest storage on ergothioneine content of common button mushroom *Agaricus bisporus* (J. Lge) Imbach (Agaricomycetidae). *Int J Med Mush* **9**, 163–176.
 300. Kalaras MD, Richie JP, Calcagnotto A, *et al.* (2017) Mushrooms: a rich source of the antioxidants ergothioneine and glutathione. *Food Chem* **233**, 429–433.
 301. Tepwong P & Ohshima T (2009) Biosynthesis of ergothioneine during different stages of submerged fermentation of “Shiitake” (*Lentinus edodes*) mushroom and their bioactive properties. *J Biosci Bioeng* **108**, S4–S5.
 302. Tepwong P, Giri A & Ohshima T (2012) Effect of mycelial morphology on ergothioneine production during liquid fermentation of *Lentinula edodes*. *Mycoscience* **53**, 102–112.
 303. Tepwong P, Giri A, Sasaki F, *et al.* (2012) Mycobial enhancement of ergothioneine by submerged cultivation of edible mushroom mycelia and its application as an antioxidative compound. *Food Chem* **131**, 247–258.
 304. Kalaras MD, Beelman RB & Elias RJ (2012) Effects of postharvest pulsed UV light treatment of white button mushrooms (*Agaricus bisporus*) on vitamin D-2 content and quality attributes. *J Agric Food Chem* **60**, 220–225.
 305. Kalaras MD, Beelman RB, Holick MF, *et al.* (2012) Generation of potentially bioactive ergosterol-derived products following pulsed ultraviolet light exposure of mushrooms (*Agaricus bisporus*). *Food Chem* **135**, 396–401.
 306. Liang CH, Ho KJ, Huang LY, *et al.* (2013) Antioxidant properties of fruiting bodies, mycelia, and fermented products of the culinary-medicinal king oyster mushroom, *Pleurotus eryngii* (higher Basidiomycetes), with high ergothioneine content. *Int J Med Mushrooms* **15**, 267–275.
 307. Lin SY, Chien SC, Wang SY, *et al.* (2015) Submerged cultivation of mycelium with high ergothioneine content from the culinary-medicinal golden oyster mushroom, *Pleurotus citrinopileatus* (higher Basidiomycetes). *Int J Med Mushrooms* **17**, 749–761.
 308. Lin SY, Chien SC, Wang SY, *et al.* (2016) Nonvolatile taste components and antioxidant properties of fruiting body and mycelium with high ergothioneine content from the culinary-medicinal golden oyster mushroom *Pleurotus citrinopileatus* (Agaricomycetes). *Int J Med Mushrooms* **18**, 689–698.
 309. Chen SY, Ho KJ, Hsieh YJ, *et al.* (2012) Contents of lovastatin, γ -aminobutyric acid and ergothioneine in mushroom fruiting bodies and mycelia. *LWT Food Sci Technol* **47**, 274–278.
 310. Peñaloza W, Davey CL, Hedger JN, *et al.* (1991) Stimulation by potassium ions of the growth of *Rhizopus oligosporus* during liquid- and solid-substrate fermentations. *World J Microbiol Biotechnol* **7**, 260–268.
 311. Peñaloza W, Davey CL, Hedger JN, *et al.* (1992) Physiological studies on the solid-state quinoa tempe fermentation, using on-line measurements of fungal biomass production. *J Sci Food Agric* **59**, 227–235.
 312. Karyadi D & Lukito W (1996) Beneficial effects of tempeh in disease prevention and treatment. *Nutr Rev* **54**, S94–S98.
 313. Lukito W (2001) Candidate foods in the Asia-Pacific region for cardiovascular protection: nuts, soy, lentils and tempe. *Asia Pac J Clin Nutr* **10**, 128–133.
 314. Nout MJR & Kiers JL (2005) Tempe fermentation, innovation and functionality: update into the third millenium. *J Appl Microbiol* **98**, 789–805.
 315. Guinard JX, Myrdal Miller A, Mills K, *et al.* (2016) Consumer acceptance of dishes in which beef has been partially substituted with mushrooms and sodium has been reduced. *Appetite* **105**, 449–459.
 316. Myrdal Miller A, Mills K, Wong T, *et al.* (2014) Flavor-enhancing properties of mushrooms in meat-based dishes in which sodium has been reduced and meat has been partially substituted with mushrooms. *J Food Sci* **79**, S1795–S1804.
 317. Royse DJ, Baars J & Tan Q (2017) Current overview of mushroom production in the world. In *Edible and Medicinal Mushrooms: Technology and Applications*, pp. 5–14 [DC Zied and A Pardo-Giménez, editors]. New York: Wiley-Blackwell.
 318. Gallego P, Rojas A, Falcón G, *et al.* (2019) Water-soluble extracts from edible mushrooms (*Agaricus bisporus*) as inhibitors of hepatitis C viral replication. *Food Funct* **10**, 3758–3767.
 319. Schmitz LK (2015) Bioavailability and antioxidant effect of ergothioneine in human blood. *MARBLE Res Pap* **6**, 174–183.
 320. Dogan A, Dalar A, Sadullahoglu C, *et al.* (2018) Investigation of the protective effects of horse mushroom (*Agaricus arvensis* Schaeff.) against carbon tetrachloride-induced oxidative stress in rats. *Mol Biol Rep* **45**, 787–797.
 321. Khatun K, Mahtab H, Khanam PA, *et al.* (2007) Oyster mushroom reduced blood glucose and cholesterol in diabetic subjects. *Mymensingh Med J* **16**, 94–99.

322. Hess J, Wang Q, Gould T, *et al.* (2018) Impact of *Agaricus bisporus* mushroom consumption on gut health markers in healthy adults. *Nutrients* **10**, E1402.
323. Chaturvedi VK, Agarwal S, Gupta KK, *et al.* (2018) Medicinal mushroom: boon for therapeutic applications. *3 Biotech* **8**, 334.
324. Moro C, Palacios I, Lozano M, *et al.* (2012) Anti-inflammatory activity of methanolic extracts from edible mushrooms in LPS activated RAW 264.7 macrophages. *Food Chem* **130**, 350–355.
325. Guillamón E, García-Lafuente A, Lozano M, *et al.* (2010) Edible mushrooms: role in the prevention of cardiovascular diseases. *Fitoterapia* **81**, 715–723.
326. Friedman M (2015) Chemistry, nutrition, and health-promoting properties of *Hericium erinaceus* (lion's mane) mushroom fruiting bodies and mycelia and their bioactive compounds. *J Agric Food Chem* **63**, 7108–7123.
327. Moon B & Lo YM (2014) Conventional and novel applications of edible mushrooms in today's food industry. *J Food Process Pres* **38**, 2146–2153.
328. Tang C, Hoo PC, Tan LT, *et al.* (2016) Golden needle mushroom: a culinary medicine with evidenced-based biological activities and health promoting properties. *Front Pharmacol* **7**, 474.
329. Jayakumar T, Sakthivel M, Thomas PA, *et al.* (2008) *Pleurotus ostreatus*, an oyster mushroom, decreases the oxidative stress induced by carbon tetrachloride in rat kidneys, heart and brain. *Chem-Biol Interact* **176**, 108–120.
330. Jayakumar T, Thomas PA, Sheu JR, *et al.* (2011) *In vitro* and *in vivo* antioxidant effects of the oyster mushroom *Pleurotus ostreatus*. *Food Res Int* **44**, 851–861.
331. Jayakumar T, Thomas PA, Ramesh E, *et al.* (2010) An extract of the *Pleurotus ostreatus* mushroom bolsters the glutathione redox system in various organs of aged rats. *J Med Food* **13**, 771–778.
332. Rahman MA, Abdullah N & Aminudin N (2017) Corroborative assessment of mushroom as the graceful ageing and lifespan promoting agent. *Biointerface Res App* **7**, 2072–2083.
333. Rahman MA, Abdullah N & Aminudin N (2016) Interpretation of mushroom as a common therapeutic agent for Alzheimer's disease and cardiovascular diseases. *Crit Rev Biotechnol* **36**, 1131–1142.
334. Feeney MJ, Dwyer J, Hasler-Lewis CM, *et al.* (2014) Mushrooms and health summit proceedings. *J Nutr* **144**, 1128S–1136S.
335. Feeney MJ, Miller AM, Roupas P (2014) Mushrooms – biologically distinct and nutritionally unique: exploring a “third food kingdom”. *Nutr Today* **49**, 301–307.
336. Kawaguchi Y, Nirengi S, Kotani K, *et al.* (2017) Mushroom intake and advanced glycation end products in the skin among community-dwelling elderly subjects: preliminary data. *J Biomed* **2**, 8–11.
337. Benson KF, Ager DM, Landes B, *et al.* (2012) Improvement of joint range of motion (ROM) and reduction of chronic pain after consumption of an ergothioneine-containing nutritional supplement. *Prev Med* **54**, Suppl., S83–S89.
338. Gargano ML, van Griensven LJLD, Isikhuemhen OS, *et al.* (2017) Medicinal mushrooms: valuable biological resources of high exploitation potential. *Plant Biosystems* **151**, 548–565.
339. Khan MA & Tania M (2012) Nutritional and medicinal importance of *Pleurotus* mushrooms: an overview. *Food Rev Int* **28**, 313–329.
340. Calvo MS, Mehrotra A, Beelman RB, *et al.* (2016) A retrospective study in adults with metabolic syndrome: diabetic risk factor response to daily consumption of *Agaricus bisporus* (white button mushrooms). *Plant Foods Hum Nutr* **71**, 245–251.
341. Mori K, Inatomi S, Ouchi K, *et al.* (2009) Improving effects of the mushroom Yamabushitake (*Hericium erinaceus*) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. *Phytother Res* **23**, 367–372.
342. Roncero-Ramos I & Delgado-Andrade C (2017) The beneficial role of edible mushrooms in human health. *Curr Opin Food Sci* **14**, 122–128.
343. Reis FS, Martins A, Vasconcelos MH, *et al.* (2017) Functional foods based on extracts or compounds derived from mushrooms. *Trends Food Sci Tech* **66**, 48–62.
344. Soković M, Glamočlija J, Ćirić A, *et al.* (2018) Mushrooms as sources of therapeutic foods. In *Therapeutic Foods*, vol. 8, pp. 141–178 [AM Holban and AM Grumezescu, editors]. Cambridge, MA: Academy Press.
345. Trovato Salinaro A, Pennisi M, Di Paola R, *et al.* (2018) Neuroinflammation and neurohormesis in the pathogenesis of Alzheimer's disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms. *Immun Ageing* **15**, 8.
346. Valverde ME, Hernandez-Perez T & Paredes-Lopez O (2015) Edible mushrooms: improving human health and promoting quality life. *Int J Microbiol* **2015**, 376387.
347. Muszyńska B, Grzywacz-Kisielewska A, Kała K, *et al.* (2018) Anti-inflammatory properties of edible mushrooms: a review. *Food Chem* **243**, 373–381.
348. Feng L, Cheah IK, Ng MM, *et al.* (2019) The association between mushroom consumption and mild cognitive impairment: a community-based cross-sectional study in Singapore. *J Alzheimers Dis* **68**, 197–203.
349. Poddar KH, Ames M, Hsin-Jen C, *et al.* (2013) Positive effect of mushrooms substituted for meat on body weight, body composition, and health parameters. A 1-year randomized clinical trial. *Appetite* **71**, 379–387.
350. Hodge AM & Calvo MS (2019) Do bioactive components in non-animal food sources contribute to the beneficial health effect of a Japanese dietary pattern? *Public Health Nutr* **22**, 2469–2471.
351. Zembron-Lacny A, Gajewski M, Naczki M, *et al.* (2013) Effect of shiitake (*Lentinus edodes*) extract on antioxidant and inflammatory response to prolonged eccentric exercise. *J Physiol Pharmacol* **64**, 249–254.
352. Jayachandran M, Xiao J & Xu B (2017) A critical review on health promoting benefits of edible mushrooms through gut microbiota. *Int J Mol Sci* **18**, E1934.
353. Maier L, Pruteanu M, Kuhn M, *et al.* (2018) Extensive impact of non-antibiotic drugs on human gut bacteria. *Nature* **555**, 623–628.
354. Schmutz M, Carron PN, Yersin B, *et al.* (2018) Mushroom poisoning: a retrospective study concerning 11-years of admissions in a Swiss emergency department. *Intern Emerg Med* **13**, 59–67.
355. Chan CK, Lam HC, Chiu SW, *et al.* (2016) Mushroom poisoning in Hong Kong: a ten-year review. *Hong Kong Med J* **22**, 124–130.
356. Verma N, Bhalla A, Kumar S, *et al.* (2014) Wild mushroom poisoning in north India: case series with review of literature. *J Clin Exp Hepatol* **4**, 361–365.
357. White J, Weinstein SA, De Haro L, *et al.* (2019) Mushroom poisoning: a proposed new clinical classification. *Toxicol* **157**, 53–65.
358. Ramirez-Martinez A, Wesolek N, Yadan JC, *et al.* (2016) Intake assessment of α -ergothioneine in some European countries and in the United States. *Hum Ecol Risk Assess* **22**, 667–677.
359. Marone PA, Trampota J, Weisman S (2016) A safety evaluation of a nature-identical α -ergothioneine in Sprague Dawley rats. *Int J Toxicol* **35**, 568–583.
360. Cheah IK, Tang RMY, Yew TSZ, *et al.* (2017) Administration of pure ergothioneine to healthy human subjects: uptake,

- metabolism, and effects on biomarkers of oxidative damage and inflammation. *Antioxid Redox Signal* **26**, 193–206.
361. Turck D, Bresson JL, Burlingame B, *et al.* (2016) Safety of synthetic L-ergothioneine (Ergoneine (R)) as a novel food pursuant to Regulation (EC) No 258/97. *EFSA J* **14**, 4629.
 362. Turck D, Bresson JL, Burlingame B, *et al.* (2017) Statement on the safety of synthetic L-ergothioneine as a novel food – supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. *EFSA J* **15**, 5060.
 363. Schauss AG, Vértési A, Endres JR, *et al.* (2010) Evaluation of the safety of the dietary antioxidant ergothioneine using the bacterial reverse mutation assay. *Toxicology* **278**, 39–45.
 364. Schauss AG, Béres E, Vértési A, *et al.* (2011) The effect of ergothioneine on clastogenic potential and mutagenic activity: genotoxicity evaluation. *Int J Toxicol* **30**, 405–409.
 365. Hunter G (1928) A new test for ergothioneine upon which is based a method for its estimation in simple solution and in blood-filtrates. *Biochem J* **22**, 4–10.
 366. Melville DB & Lubschez R (1953) A method for the determination of ergothioneine in blood. *J Biol Chem* **200**, 275–285.
 367. Carlsson J, Kierstan MP & Brocklehurst K (1974) A convenient spectrophotometric assay for the determination of L-ergothioneine in blood. *Biochem J* **139**, 237–242.
 368. Sotgia S, Arru D, Sotgiu E, *et al.* (2016) Simultaneous determination of the main amino thiol and thione in human whole blood by CE and LC. *Bioanalysis* **8**, 945–951.
 369. Sotgia S, Pisanu E, Pintus G, *et al.* (2013) Plasma L-ergothioneine measurement by high-performance liquid chromatography and capillary electrophoresis after a pre-column derivatization with 5-iodoacetamidofluorescein (5-IAF) and fluorescence detection. *PLOS ONE* **8**, e70374.
 370. Zhou T, Liu Q, Jiang W, *et al.* (2012) A new strategy for quantitative analysis of ergothioneine in fermentation broth by RP-HPLC. *Lect Notes Elec Eng* **249**, 313–321.
 371. Mayumi T, Kawano H, Sakamoto Y, *et al.* (1978) Studies on ergothioneine. V. Determination by high performance liquid chromatography and application to metabolic research. *Chem Pharm Bull (Tokyo)* **26**, 3772–3778.
 372. Sotgia S, Zinellu A, Arru D, *et al.* (2015) Amniotic fluid L-ergothioneine concentrations in pregnant sheep after natural mating and transfer of vitrified/thawed *in-vitro* produced embryos. *Res Vet Sci* **102**, 238–241.
 373. Liu Q, Zhang W, Wang H, *et al.* (2016) Validation of a HILIC method for the analysis of ergothioneine in fermentation broth. *J Chromatogr Sci* **54**, 934–938.
 374. Muda M, Pelizzoni F, Sello G, *et al.* (1988) Determination of ergothioneine in red blood cells by high-performance liquid chromatography. *J Chromatogr* **434**, 191–195.
 375. Newton GL, Dorian R & Fahey RC (1981) Analysis of biological thiols: derivatization with monobromobimane and separation by reverse-phase high-performance liquid chromatography. *Anal Biochem* **114**, 383–387.
 376. Bello MH, Mogannam JC, Morin D, *et al.* (2014) Endogenous ergothioneine is required for wild type levels of conidiogenesis and conidial survival but does not protect against 254 nm UV-induced mutagenesis or kill. *Fungal Genet Biol* **73**, 120–127.
 377. Fahey RC & Newton GL (1987) Determination of low-molecular-weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. *Methods Enzymol* **143**, 85–96.
 378. Sotgia S, Pisanu E, Cambedda D, *et al.* (2014) Ultra-performance liquid chromatographic determination of L-ergothioneine in commercially available classes of cow milk. *J Food Sci* **79**, C1683–C1687.
 379. Kuninori T & Nishiyama J (1991) Measurement of biological thiols and disulfides by high-performance liquid chromatography and electrochemical detection of silver mercaptide formation. *Anal Biochem* **197**, 19–24.
 380. Kroepfl N, Francesconi KA, Schwerdtle T, *et al.* (2019) Selenoneine and ergothioneine in human blood cells determined simultaneously by HPLC/ICPQQQ-MS. *J Anal At Spectrom* **34**, 127–134.
 381. Bashir R (2017) Bio-analytical screening and characterization of antioxidant compounds using online liquid chromatography techniques and mass spectrometry. Thesis for Doctor of Philosophy, Swinburne University of Technology.
 382. Sotgia S, Zinellu A, Pintus G, *et al.* (2013) Quantification of L-ergothioneine in whole blood by hydrophilic interaction ultra-performance liquid chromatography and UV-detection. *J Sep Sci* **36**, 1002–1006.
 383. Sakurai H & Takeshima S (1977) Acid dissociation of 2-mercaptohistamine and its related compounds. *Talanta* **24**, 531–532.
 384. Bessieres MA, Gibon Y, Lefeuvre JC, *et al.* (1999) A single-step purification for glycine betaine determination in plant extracts by isocratic HPLC. *J Agric Food Chem* **47**, 3718–3722.
 385. Kar JR & Singhal RS (2017) Pilot scale production, kinetic modeling, and purification of glycine betaine and trehalose produced from *Actinopolyspora halophila* (MTCC 263) using acid whey: a dairy industry effluent. *Chem Eng Sci* **163**, 83–91.
 386. Bubnik Z, Pour V, Gruberova A, *et al.* (2004) Application of continuous chromatographic separation in sugar processing. *J Food Eng* **61**, 509–513.
 387. Kumosani TA (2001) L-Ergothioneine level in red blood cells of healthy human males in the Western province of Saudi Arabia. *Exp Mol Med* **33**, 20–22.
 388. Baldrige RC & Lewis HB (1953) Diet and the ergothioneine content of blood. *J Biol Chem* **202**, 169–176.
 389. Baldrige RC (1955) Blood ergothioneine and dietary oats. *J Nutr* **56**, 107–113.
 390. Teruya T, Chaleckis R, Takada J, *et al.* (2019) Diverse metabolic reactions activated during 58-hr fasting are revealed by non-targeted metabolomic analysis of human blood. *Sci Rep* **9**, 854.
 391. Cheah IK, Feng L, Tang RMY, *et al.* (2016) Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration? *Biochem Biophys Res Commun* **478**, 162–167.
 392. Yan S, Wu B, Lin Z, *et al.* (2009) Metabonomic characterization of aging and investigation on the anti-aging effects of total flavones of *Epimedium*. *Mol Biosyst* **5**, 1204–1213.
 393. Dang VT, Shi Y & Werstuck G (2015) Comprehensive metabolomic analysis of diabetic atherosclerosis. *Can J Cardiol* **31**, S229.
 394. Leone E, Mann T (1951) Ergothioneine in the seminal vesicle secretion. *Nature* **168**, 205–206.
 395. Strzeżek R, Koziorowska-Gilun M, Kowalowka M, *et al.* (2009) Characteristics of antioxidant system in dog semen. *Pol J Vet Sci* **12**, 55–60.
 396. Strzeżek R, Koziorowska-Gilun M, Kielczewski K, *et al.* (2015) Effect of dialysis of dog semen on sperm characteristics and some biochemical components of seminal plasma. *Pol J Vet Sci* **18**, 447–448.
 397. Kenny LC & Kell DB (2018) Immunological tolerance, pregnancy and preeclampsia: the roles of semen microbes and the father. *Front Med Obs Gynecol* **4**, 239.
 398. Forster R, Spézia F, Papineau D, *et al.* (2015) Reproductive safety evaluation of L-ergothioneine. *Food Chem Toxicol* **80**, 85–91.
 399. Mishra A, Reddy JJ, Dhali A, *et al.* (2018) L-Ergothioneine improves the developmental potential of *in vitro* sheep embryos

- without influencing OCTN1-mediated cross-membrane transcript expression. *Zygote* **26**, 149–161.
400. Shukla Y, Kulshrestha OP & Khuteta KP (1981) Ergothioneine content in normal and senile human cataractous lenses. *Indian J Med Res* **73**, 472–473.
 401. Kato Y, Kubo Y, Iwata D, *et al.* (2010) Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. *Pharm Res* **27**, 832–840.
 402. Chaleckis R, Murakami I, Takada J, *et al.* (2016) Individual variability in human blood metabolites identifies age-related differences. *Proc Natl Acad Sci U S A* **113**, 4252–4259.
 403. Jose JM (2011) Ergothioneine degradation and properties of ergothionase from *Agrobacterium radiobacter*. BSc Thesis, Penn State University.
 404. Kelly B, Appleman MD (1961) Degradation of ergothioneine by cell-free extracts of *Alcaligenes faecalis*. *J Bacteriol* **81**, 715–720.
 405. Muramatsu H, Matsuo H, Okada N, *et al.* (2013) Characterization of ergothionase from *Burkholderia* sp. HME13 and its application to enzymatic quantification of ergothioneine. *Appl Microbiol Biotechnol* **97**, 5389–5400.
 406. Yanasugondha D & Appleman MD (1957) Degradation of ergothioneine by *Alcaligenes faecalis*. *J Bacteriol* **74**, 381–385.
 407. Fennema D, Phillips IR & Shephard EA (2016) Trimethylamine and trimethylamine *N*-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. *Drug Metab Dispos* **44**, 1839–1850.
 408. Wolff JB (1962) Ergothionase from *Escherichia coli*. *J Biol Chem* **237**, 874–881.
 409. Maurer A, Leisinger F, Lim D, *et al.* (2019) Structure and mechanism of ergothionase from *Treponema denticola*. *Chemistry* **25**, 10298–10303.
 410. Booth JS, Appleman MD (1963) Degradation of ergothioneine by cell-free extracts of *Alcaligenes faecalis*. II. Production of glutamic acid. *J Bacteriol* **85**, 654–657.
 411. Cheah IK, Ong RL, Gruber J, *et al.* (2013) Knockout of a putative ergothioneine transporter in *Caenorhabditis elegans* decreases lifespan and increases susceptibility to oxidative damage. *Free Radic Res* **47**, 1036–1045.
 412. Ben Said M, Grati M, Ishimoto T, *et al.* (2016) A mutation in SLC22A4 encoding an organic cation transporter expressed in the cochlea stria endothelium causes human recessive non-syndromic hearing loss DFNB60. *Hum Genet* **135**, 513–524.
 413. Urban TJ, Yang C, Lagpacan LL, *et al.* (2007) Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). *Pharmacogenet Genomics* **17**, 773–782.
 414. Toh DSL, Koo SH, Limenta LMG, *et al.* (2009) Genetic variations of the SLC22A4 gene in Chinese and Indian populations of Singapore. *Drug Metab Pharmacokinet* **24**, 475–481.
 415. Toh DSL, Cheung FSG, Murray M, *et al.* (2013) Functional analysis of novel variants in the organic cation/ergothioneine transporter 1 identified in Singapore populations. *Mol Pharm* **10**, 2509–2516.
 416. Mathieson I, Lazaridis I, Rohland N, *et al.* (2015) Genome-wide patterns of selection in 230 ancient Eurasians. *Nature* **528**, 499–503.
 417. Yamase Y, Horibe H, Ueyama C, *et al.* (2015) Association of TOMM40 and SLC22A4 polymorphisms with ischemic stroke. *Biomed Rep* **3**, 491–498.
 418. Nakamura T, Sugiura S, Kobayashi D, *et al.* (2007) Decreased proliferation and erythroid differentiation of K562 cells by siRNA-induced depression of OCTN1 (SLC22A4) transporter gene. *Pharm Res* **24**, 1628–1635.
 419. Maeda T, Hirayama M, Kobayashi D, *et al.* (2007) Mechanism of the regulation of organic cation/carnitine transporter 1 (SLC22A4) by rheumatoid arthritis-associated transcriptional factor RUNX1 and inflammatory cytokines. *Drug Metab Dispos* **35**, 394–401.
 420. Tokuhira S, Yamada R, Chang X, *et al.* (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. *Nat Genet* **35**, 341–348.
 421. Reglinski J, Smith WE & Sturrock RD (1988) Spin-echo ¹H NMR detected response of ergothioneine to oxidative stress in the intact human erythrocyte. *Magn Reson Med* **6**, 217–223.
 422. Takata Y, Inoue H, Sato A, *et al.* (2008) Replication of reported genetic associations of PADI4, FCRL3, SLC22A4 and RUNX1 genes with rheumatoid arthritis: results of an independent Japanese population and evidence from meta-analysis of East Asian studies. *J Hum Genet* **53**, 163–173.
 423. Barton A, Eyre S, Bowes J, *et al.* (2005) Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. *Arthritis Rheum* **52**, 752–758.
 424. Han TU, Lee HS, Kang C, *et al.* (2015) Association of joint erosion with SLC22A4 gene polymorphisms inconsistently associated with rheumatoid arthritis susceptibility. *Autoimmunity* **48**, 313–317.
 425. Martínez A, Valdivia A, Pascual-Salcedo D, *et al.* (2006) Role of SLC22A4, SLC22A5, and RUNX1 genes in rheumatoid arthritis. *J Rheumatol* **33**, 842–846.
 426. Yamada R, Tokuhira S, Chang X, *et al.* (2004) SLC22A4 and RUNX1: identification of RA susceptible genes. *J Mol Med (Berl)* **82**, 558–564.
 427. Lee YH, Bae SC, Kim JH, *et al.* (2015) Meta-analysis of SLC22A4 and RUNX1 polymorphisms: associations with rheumatoid arthritis susceptibility. *Z Rheumatol* **74**, 351–358.
 428. Orozco G, Sánchez E, Gómez LM, *et al.* (2006) Study of the role of functional variants of SLC22A4, RUNX1 and SUMO4 in systemic lupus erythematosus. *Ann Rheum Dis* **65**, 791–795.
 429. Taubert D, Grimberg G, Jung N, *et al.* (2005) Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn's disease. *Gut* **54**, 1505–1506.
 430. Taubert D, Jung N, Goesser T, *et al.* (2009) Increased ergothioneine tissue concentrations in carriers of the Crohn's disease risk-associated 503F variant of the organic cation transporter OCTN1. *Gut* **58**, 312–314.
 431. Jung ES, Park HJ, Kong KA, *et al.* (2017) Association study between OCTN1 functional haplotypes and Crohn's disease in a Korean population. *Korean J Physiol Pharmacol* **21**, 11–17.
 432. Lai Y, Xue J, Liu CW, *et al.* (2019) Serum metabolomics identifies altered bioenergetics, signaling cascades in parallel with exposome markers in Crohn's disease. *Molecules* **24**, 449.
 433. Huff CD, Witherspoon DJ, Zhang Y, *et al.* (2012) Crohn's disease and genetic hitchhiking at IBD5. *Mol Biol Evol* **29**, 101–111.
 434. Peltekova VD, Wintle RF, Rubin LA, *et al.* (2004) Functional variants of OCTN cation transporter genes are associated with Crohn disease. *Nat Genet* **36**, 471–475.
 435. Newman B, Gu X, Wintle R, *et al.* (2005) A risk haplotype in the solute carrier family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. *Gastroenterology* **128**, 260–269.
 436. Leung E, Hong J, Fraser AG, *et al.* (2006) Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5

- and Crohn's disease in a New Zealand Caucasian cohort. *Immunol Cell Biol* **84**, 233–236.
437. Santiago JL, Martinez A, de la Calle H, *et al.* (2006) Evidence for the association of the SLC22A4 and SLC22A5 genes with type 1 diabetes: a case control study. *BMC Med Genet* **7**, 54.
438. Zhao Z, Reece EA (2013) New concepts in diabetic embryopathy. *Clin Lab Med* **33**, 207–233.
439. Wada E, Koyanagi S, Kusunose N, *et al.* (2015) Modulation of peroxisome proliferator-activated receptor- α activity by bile acids causes circadian changes in the intestinal expression of Octn1/Slc22a4 in mice. *Mol Pharmacol* **87**, 314–322.
440. Mestres J, Gregori-Puigjané E, Valverde S, *et al.* (2009) The topology of drug-target interaction networks: implicit dependence on drug properties and target families. *Mol Biosyst* **5**, 1051–1057.
441. Kell DB (2006) Metabolomics, modelling and machine learning in systems biology: towards an understanding of the languages of cells. The 2005 Theodor Bücher lecture. *FEBS J* **273**, 873–894.
442. Palsson BØ (2015) *Systems Biology: Constraint-Based Reconstruction and Analysis*. Cambridge: Cambridge University Press.
443. Sastry AV, Gao Y, Szubin R, *et al.* (2019) The *Escherichia coli* transcriptome consists of independently regulated modules. *Nat Commun* **10**, 5536.
444. Kell DB (2005) Metabolomics, machine learning and modelling: towards an understanding of the language of cells. *Biochem Soc Trans* **33**, 520–524.
445. Kell DB & Knowles JD (2006) The role of modeling in systems biology. In *System Modeling in Cellular Biology: From Concepts to Nuts and Bolts*, pp. 3–18 [Z Szallasi, J Stelling and V Periwal, editors]. Cambridge, MA: MIT Press.
446. Ihekweba AEC, Broomhead DS, Grimley R, *et al.* (2004) Sensitivity analysis of parameters controlling oscillatory signalling in the NF- κ B pathway: the roles of IKK and I κ B α . *Systems Biol* **1**, 93–103.
447. Saltelli A, Tarantola S, Campolongo F, *et al.* (2004) *Sensitivity Analysis in Practice: A Guide to Assessing Scientific Models*. New York: Wiley.
448. Rand DA (2008) Mapping global sensitivity of cellular network dynamics: sensitivity heat maps and a global summation law. *J R Soc Interface* **5**, Suppl. 1, S59–S69.
449. Kell DB & Oliver SG (2004) Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. *Bioessays* **26**, 99–105.
450. Ledoux AC & Perkins ND (2014) NF- κ B and the cell cycle. *Biochem Soc Trans* **42**, 76–81.
451. Perkins ND (2012) The diverse and complex roles of NF- κ B subunits in cancer. *Nat Rev Cancer* **12**, 121–132.
452. Shih RH, Wang CY & Yang CM (2015) NF- κ B signaling pathways in neurological inflammation: a mini review. *Front Mol Neurosci* **8**, 77.
453. Nelson DE, Ihekweba AEC, Elliott M, *et al.* (2004) Oscillations in NF- κ B signalling control the dynamics of gene expression. *Science* **306**, 704–708.
454. Ashall L, Horton CA, Nelson DE, *et al.* (2009) Pulsatile stimulation determines timing and specificity of NF- κ B-dependent transcription. *Science* **324**, 242–246.
455. Buelna-Chontal M & Zazueta C (2013) Redox activation of Nrf2 & NF- κ B: a double end sword? *Cell Signal* **25**, 2548–2557.
456. Kaur U, Banerjee P, Bir A, *et al.* (2015) Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer's disease: the NF- κ B connection. *Curr Top Med Chem* **15**, 446–457.
457. Lepetsos P, Papavassiliou KA & Papavassiliou AG (2019) Redox and NF- κ B signaling in osteoarthritis. *Free Radic Biol Med* **132**, 90–100.
458. Gao G & Dudley SC Jr (2009) Redox regulation, NF- κ B, and atrial fibrillation. *Antioxid Redox Signal* **11**, 2265–2277.
459. Xiao L, Zhao L, Li T, *et al.* (2006) Activity of the dietary antioxidant ergothioneine in a virus gene-based assay for inhibitors of HIV transcription. *Biofactors* **27**, 157–165.
460. Rahman I, Gilmour PS, Jimenez LA, *et al.* (2003) Ergothioneine inhibits oxidative stress- and TNF- α -induced NF- κ B activation and interleukin-8 release in alveolar epithelial cells. *Biochem Biophys Res Commun* **302**, 860–864.
461. Agarwal A, Aponte-Mellado A, Premkumar BJ, *et al.* (2012) The effects of oxidative stress on female reproduction: a review. *Reprod Biol Endocrinol* **10**, 49.
462. Aouache R, Biquard L, Vaiman D, *et al.* (2018) Oxidative stress in preeclampsia and placental diseases. *Int J Med Sci* **19**.
463. Wang J, Schipper HM, Velly AM, *et al.* (2015) Salivary biomarkers of oxidative stress: a critical review. *Free Radic Biol Med* **85**, 95–104.
464. Schrag M, Mueller C, Zabel M, *et al.* (2013) Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis. *Neurobiol Dis* **59**, 100–110.
465. Jones DP (2006) Redefining oxidative stress. *Antioxid Redox Signal* **8**, 1865–1879.
466. Rice-Evans CA & Packer L (editors) (2003) *Flavonoids in Health and Disease*, 2nd ed. New York: Marcel Dekker.
467. Halliwell B & Gutteridge JMC (2006) *Free Radicals in Biology and Medicine*, 4th ed. Oxford: Oxford University Press.
468. Halliwell B & Gutteridge JMC (2015) *Free Radicals in Biology and Medicine*, 5th ed. Oxford: Oxford University Press.
469. Deiana M, Rosa A, Casu V, *et al.* (2004) L-Ergothioneine modulates oxidative damage in the kidney and liver of rats *in vivo*: studies upon the profile of polyunsaturated fatty acids. *Clin Nutr* **23**, 183–193.
470. Laurenza I, Colognato R, Migliore L, *et al.* (2008) Modulation of palmitic acid-induced cell death by ergothioneine: evidence of an anti-inflammatory action. *Biofactors* **33**, 237–247.
471. Gökçe G, Arun MZ & Ertuna E (2018) Ergothioneine prevents endothelial dysfunction induced by mercury chloride. *Exp Ther Med* **15**, 4697–4702.
472. Rai RK, Chalana A, Karri R, *et al.* (2019) Role of hydrogen bonding by thiones in protecting biomolecules from copper(I)-mediated oxidative damage. *Inorg Chem* **58**, 6628–6638.
473. Zhu BZ, Mao L, Fan RM, *et al.* (2011) Ergothioneine prevents copper-induced oxidative damage to DNA and protein by forming a redox-inactive ergothioneine-copper complex. *Chem Res Toxicol* **24**, 30–34.
474. Gokce G & Arun MZ (2014) Ergothioneine produces relaxation in isolated rat aorta by inactivating superoxide anion. *Eur Rev Med Pharmacol Sci* **18**, 3339–3345.
475. Pahila J, Ishikawa Y & Ohshima T (2019) Effects of ergothioneine-rich mushroom extract on the oxidative stability of astaxanthin in liposomes. *J Agric Food Chem* **67**, 3491–3501.
476. Cheah IK, Tang R, Ye P, *et al.* (2016) Liver ergothioneine accumulation in a guinea pig model of non-alcoholic fatty liver disease. A possible mechanism of defence? *Free Radic Res* **50**, 14–25.
477. Sansbury BE, DeMartino AM, Xie Z, *et al.* (2014) Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. *Circ Heart Fail* **7**, 634–642.
478. Agudo-Barruso M, Lahoz A, Nadal-Nicolás FM, *et al.* (2013) Metabolomic changes in the rat retina after optic nerve crush. *Invest Ophthalmol Vis Sci* **54**, 4249–4259.

479. Colognato R, Laurenza I, Fontana I, *et al.* (2006) Modulation of hydrogen peroxide-induced DNA damage, MAPKs activation and cell death in PC12 by ergothioneine. *Clin Nutr* **25**, 135–145.
480. Song TY, Chen CL, Liao JW, *et al.* (2010) Ergothioneine protects against neuronal injury induced by cisplatin both *in vitro* and *in vivo*. *Food Chem Toxicol* **48**, 3492–3499.
481. Nishida K, Takeuchi K, Hosoda A, *et al.* (2018) Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. *Life Sci* **207**, 516–524.
482. D'Onofrio N, Servillo L, Giovane A, *et al.* (2016) Ergothioneine oxidation in the protection against high-glucose induced endothelial senescence: involvement of SIRT1 and SIRT6. *Free Radic Biol Med* **96**, 211–222.
483. Gunawardena D, Bennett L, Shanmugam K, *et al.* (2014) Anti-inflammatory effects of five commercially available mushroom species determined in lipopolysaccharide and interferon- γ activated murine macrophages. *Food Chem* **148**, 92–96.
484. Sakrak O, Kerem M, Bedirli A, *et al.* (2008) Ergothioneine modulates proinflammatory cytokines and heat shock protein 70 in mesenteric ischemia and reperfusion injury. *J Surg Res* **144**, 36–42.
485. Bedirli A, Sakrak O, Muhtaroglu S, *et al.* (2004) Ergothioneine pretreatment protects the liver from ischemia–reperfusion injury caused by increasing hepatic heat shock protein 70. *J Surg Res* **122**, 96–102.
486. Arduini A, Eddy L & Hochstein P (1990) The reduction of ferryl myoglobin by ergothioneine: a novel function for ergothioneine. *Arch Biochem Biophys* **281**, 41–43.
487. Zimring JC, Smith N, Stowell SR, *et al.* (2014) Strain-specific red blood cell storage, metabolism, and eicosanoid generation in a mouse model. *Transfusion* **54**, 137–148.
488. Kell DB & Pretorius E (2015) On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. *Integr Biol* **7**, 1339–1377.
489. Goodman M, Bostick RM, Kucuk O, *et al.* (2011) Clinical trials of antioxidants as cancer prevention agents: past, present, and future. *Free Radic Biol Med* **51**, 1068–1084.
490. Lloret A, Esteve D, Monllor P, *et al.* (2019) The effectiveness of vitamin E treatment in Alzheimer's disease. *Int J Mol Sci* **20**, E879.
491. Lloret A, Badía MC, Mora NJ, *et al.* (2009) Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. *J Alzheimers Dis* **17**, 143–149.
492. Poston L, Briley AL, Seed PT, *et al.* (2006) Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. *Lancet* **367**, 1145–1154.
493. Oldham KM & Bowen PE (1998) Oxidative stress in critical care: is antioxidant supplementation beneficial? *J Am Diet Assoc* **98**, 1001–1008.
494. Rehman A, Collis CS, Yang M, *et al.* (1998) The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers. *Biochem Biophys Res Comm* **246**, 293–298.
495. Cuzzocrea S, Riley DP, Caputi AP, *et al.* (2001) Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. *Pharmacol Rev* **53**, 135–159.
496. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, *et al.* (2002) Antioxidant therapy in acute central nervous system injury: current state. *Pharmacol Rev* **54**, 271–284.
497. Miller ER 3rd, Pastor-Barriuso R, Dalal D, *et al.* (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* **142**, 37–46.
498. Vaziri ND & Rodriguez-Iturbe B (2006) Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. *Nat Clin Pract Nephrol* **2**, 582–593.
499. Rodrigo R, Guichard C & Charles R (2007) Clinical pharmacology and therapeutic use of antioxidant vitamins. *Fund Clin Pharmacol* **21**, 111–127.
500. Bjelakovic G, Nikolova D, Gluud LL, *et al.* (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA* **297**, 842–857.
501. Bjelakovic G, Nikolova D, Gluud LL, *et al.* (2008) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev*, issue 2, CD007176.
502. Mendes-da-Silva RF, Lopes-de-Morais AA, Bandim-da-Silva ME, *et al.* (2014) Prooxidant versus antioxidant brain action of ascorbic acid in well-nourished and malnourished rats as a function of dose: a cortical spreading depression and malondialdehyde analysis. *Neuropharmacology* **86**, 155–160.
503. Zhang P & Omaye ST (2001) Antioxidant and prooxidant roles for β -carotene, α -tocopherol and ascorbic acid in human lung cells. *Toxicol In Vitro* **15**, 13–24.
504. Ullah MF, Khan HY, Zubair H, *et al.* (2011) The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. *Cancer Chemother Pharmacol* **67**, 103–110.
505. Repine JE & Elkins ND (2012) Effect of ergothioneine on acute lung injury and inflammation in cytokine insufflated rats. *Prev Med* **54**, Suppl., S79–S82.
506. Martin KR (2010) The bioactive agent ergothioneine, a key component of dietary mushrooms, inhibits monocyte binding to endothelial cells characteristic of early cardiovascular disease. *J Med Food* **13**, 1340–1346.
507. Servillo L, D'Onofrio N & Balestrieri ML (2017) Ergothioneine antioxidant function: from chemistry to cardiovascular therapeutic potential. *J Cardiovasc Pharmacol* **69**, 183–191.
508. Darghouth D, Koehl B, Heilier JF, *et al.* (2011) Alterations of red blood cell metabolome in overhydrated hereditary stomatocytosis. *Haematologica* **96**, 1861–1865.
509. Smith E, Ottosson F, Hellstrand S, *et al.* (2019) Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. *Heart* **2019**, heartjnl-2019-315485 (epublication ahead of print version 31 October 2019).
510. Nurk E, Refsum H, Drevon CA, *et al.* (2010) Cognitive performance among the elderly in relation to the intake of plant foods. The Hordaland Health Study. *Br J Nutr* **104**, 1190–1201.
511. Zhang S, Tomata Y, Sugiyama K, *et al.* (2017) Mushroom consumption and incident dementia in elderly Japanese: the Ohsaki Cohort 2006 Study. *J Am Geriatr Soc* **65**, 1462–1469.
512. Phan CW, David P & Sabaratnam V (2017) Edible and medicinal mushrooms: emerging brain food for the mitigation of neurodegenerative diseases. *J Med Food* **20**, 1–10.
513. Thangthaeng N, Miller MG, Gomes SM, *et al.* (2015) Daily supplementation with mushroom (*Agaricus bisporus*) improves balance and working memory in aged rats. *Nutr Res* **35**, 1079–1084.
514. Tsuk S, Lev YH, Rotstein A, *et al.* (2017) Clinical effects of a commercial supplement of *Ophiocordyceps sinensis* and *Ganoderma lucidum* on cognitive function of healthy young volunteers. *Int J Med Mushrooms* **19**, 667–673.
515. Hatano T, Saiki S, Okuzumi A, *et al.* (2016) Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. *J Neurol Neurosurg Psychiatry* **87**, 295–301.

516. Hang L, Basil AH & Lim KL (2016) Nutraceuticals in Parkinson's disease. *Neuromolecular Med* **18**, 306–321.
517. Shao Y & Le W (2019) Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease. *Mol Neurodegener* **14**, 3.
518. Shah SP & Duda JE (2015) Dietary modifications in Parkinson's disease: a neuroprotective intervention? *Med Hypotheses* **85**, 1002–1005.
519. Graham SF, Chevallier OP, Kumar P, *et al.* (2017) Metabolomic profiling of brain from infants who died from sudden infant death syndrome reveals novel predictive biomarkers. *J Perinatol* **37**, 91–97.
520. Yang NC, Lin HC, Wu JH, *et al.* (2012) Ergothioneine protects against neuronal injury induced by β -amyloid in mice. *Food Chem Toxicol* **50**, 3902–3911.
521. Cheah IK, Ng LT, Ng LF, *et al.* (2019) Inhibition of amyloid-induced toxicity by ergothioneine in a transgenic *Caenorhabditis elegans* model. *FEBS Lett* **593**, 2139–2150.
522. Nakamichi N, Nakayama K, Ishimoto T, *et al.* (2016) Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice. *Brain Behav* **6**, e00477.
523. Logan AS, Nienaber U & Pan XS (editors) (2013) *Lipid Oxidation: Challenges in Food Systems*. Urbana, IL: AOCS Press.
524. Gray JI, Goma EA & Buckley DJ (1996) Oxidative quality and shelf life of meats. *Meat Sci* **43**, S111–S123.
525. Gülçin I (2012) Antioxidant activity of food constituents: an overview. *Arch Toxicol* **86**, 345–391.
526. Perron NR & Brumaghim JL (2009) A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. *Cell Biochem Biophys* **53**, 75–100.
527. Hanlon DP (1971) Interaction of ergothioneine with metal ions and metalloenzymes. *J Med Chem* **14**, 1084–1087.
528. Encarnacion AB, Fagutao F, Hirono I, *et al.* (2010) Effects of ergothioneine from mushrooms (*Flammulina velutipes*) on melanosis and lipid oxidation of kuruma shrimp (*Marsupenaeus japonicus*). *J Agric Food Chem* **58**, 2577–2585.
529. Encarnacion AB, Fagutao F, Hirayama J, *et al.* (2011) Edible mushroom (*Flammulina velutipes*) extract inhibits melanosis in Kuruma shrimp (*Marsupenaeus japonicus*). *J Food Sci* **76**, C52–C58.
530. Bao HND, Ushio H & Ohshima T (2009) Antioxidative activities of mushroom (*Flammulina velutipes*) extract added to bigeye tuna meat: dose-dependent efficacy and comparison with other biological antioxidants. *J Food Sci* **74**, C162–C169.
531. Encarnacion AB, Fagutao F, Jintasataporn O, *et al.* (2012) Application of ergothioneine-rich extract from an edible mushroom *Flammulina velutipes* for melanosis prevention in shrimp, *Penaeus monodon* and *Litopenaeus vannamei*. *Food Res Int* **45**, 232–237.
532. Cai LY, Li XP, Wu XS, *et al.* (2014) Effect of chitosan coating enriched with ergothioneine on quality changes of Japanese sea bass (*Lateolabrax japonicus*). *Food Bioproc Technol* **7**, 2281–2290.
533. Pahila J, Kaneda H, Nagasaka R, *et al.* (2017) Effects of ergothioneine-rich mushroom extracts on lipid oxidation and discoloration in salmon muscle stored at low temperatures. *Food Chem* **233**, 273–281.
534. Bao HND, Ushio H & Ohshima T (2008) Antioxidative activity and antidiscoloration efficacy of ergothioneine in mushroom (*Flammulina velutipes*) extract added to beef and fish meats. *J Agric Food Chem* **56**, 10032–10040.
535. Bao HND, Osako K & Ohshima T (2010) Value-added use of mushroom ergothioneine as a colour stabilizer in processed fish meats. *J Sci Food Agric* **90**, 1634–1641.
536. Muszyńska B & Sułkowska-Ziaja K (2015) Impact of food processing on non-hallucinogenic indole derivatives in edible mushrooms. In *Processing and Impact on Active Components in Food*, pp. 55–62 [V Preedy, editor]. San Diego, CA: Academic Press.
537. Cremades O, Diaz-Herrero MM, Carbonero-Aguilar P, *et al.* (2015) White button mushroom ergothioneine in aqueous extracts obtained by the application of enzymes and membrane technology. *Food Biosci* **10**, 42–47.
538. Sánchez C (2017) Reactive oxygen species and antioxidant properties from mushrooms. *Synth Syst Biotechnol* **2**, 13–22.
539. Duy Bao HN & Ohshima T (2013) Strategies to minimize oxidative deterioration in aquatic food products: application of natural antioxidants from edible mushrooms. In *Lipid Oxidation*, pp. 345–380 [U Nienaber and X Pan, editors]. Urbana, IL: AOCS Press.
540. Pérez-Sánchez A, Barrajón-Catalán E, Herranz-López M, *et al.* (2018) Nutraceuticals for skin care: a comprehensive review of human clinical studies. *Nutrients* **10**, E403.
541. Lee CM (2016) Fifty years of research and development of cosmeceuticals: a contemporary review. *J Cosmet Dermatol* **15**, 527–539.
542. Epstein H (2009) Cosmeceuticals and polyphenols. *Clin Dermatol* **27**, 475–478.
543. Taofiq O, González-Paramás AM, Martins A, *et al.* (2016) Mushrooms extracts and compounds in cosmetics, cosmeceuticals and nutricosmetics – a review. *Industrial Crops Products* **90**, 38–48.
544. Wu Y, Choi M-H, Li J, *et al.* (2016) Mushroom cosmetics: the present and future. *Cosmetics* **3**, 22.
545. Linder J (2012) Cosmeceutical treatment of the aging face. In *Aesthetic Medicine*, pp. 69–84 [PM Prendergast and MA Shiffman, editors]. Berlin: Springer.
546. Cronin H, Draelos ZD (2010) Top 10 botanical ingredients in 2010 anti-aging creams. *J Cosmet Dermatol* **9**, 218–225.
547. Souyoul SA, Saussy KP & Lupo MP (2018) Nutraceuticals: a review. *Dermatol Ther (Heidelb)* **8**, 5–16.
548. Norins AL (1962) Free radical formation in the skin following exposure to ultraviolet light. *J Invest Dermatol* **39**, 445–448.
549. Hseu YC, Lo HW, Korivi M, *et al.* (2015) Dermato-protective properties of ergothioneine through induction of Nrf2/ARE-mediated antioxidant genes in UVA-irradiated human keratinocytes. *Free Radic Biol Med* **86**, 102–117.
550. Botta C, Di Giorgio C, Sabatier AS, *et al.* (2008) Genotoxicity of visible light (400–800 nm) and photoprotection assessment of ectoin, *l*-ergothioneine and mannitol and four sunscreens. *J Photochem Photobiol B* **91**, 24–34.
551. Bazela K, Solyga-Zurek A, Debowska R, *et al.* (2014) *l*-Ergothioneine protects skin cells against UV-induced damage – a preliminary study. *Cosmetics* **1**, 51–60.
552. Sao Emani C, Williams MJ, Van Helden PD, *et al.* (2018) γ -Glutamylcysteine protects ergothioneine-deficient *Mycobacterium tuberculosis* mutants against oxidative and nitrosative stress. *Biochem Biophys Res Commun* **495**, 174–178.
553. Sao Emani C, Williams MJ, Van Helden PD, *et al.* (2018) Generation and characterization of thiol-deficient *Mycobacterium tuberculosis* mutants. *Sci Data* **5**, 180184.
554. Jothivasan VK & Hamilton CJ (2008) Mycothiol: synthesis, biosynthesis and biological functions of the major low molecular weight thiol in actinomycetes. *Nat Prod Rep* **25**, 1091–1117.
555. Feng J, Che Y, Milse J, *et al.* (2006) The gene *ncgl2918* encodes a novel maleylpyruvate isomerase that needs mycothiol as cofactor and links mycothiol biosynthesis and gentisate

- assimilation in *Corynebacterium glutamicum*. *J Biol Chem* **281**, 10778–10785.
556. Newton GL, Buchmeier N & Fahey RC (2008) Biosynthesis and functions of mycothiol, the unique protective thiol of Actinobacteria. *Microbiol Mol Biol Rev* **72**, 471–494.
557. Bzymek KP, Newton GL, Ta P, *et al.* (2007) Mycothiol import by *Mycobacterium smegmatis* and function as a resource for metabolic precursors and energy production. *J Bacteriol* **189**, 6796–6805.
558. Brummel MC (1985) In search of a physiological function for L-ergothioneine. *Med Hypotheses* **18**, 351–370.
559. Brummel MC (1989) In search of a physiological function for L-ergothioneine – II. *Med Hypotheses* **30**, 39–48.
560. Wang M, Zhao Q & Liu W (2015) The versatile low-molecular-weight thiols: beyond cell protection. *Bioessays* **37**, 1262–1267.
561. Zhao Q, Wang M, Xu D, *et al.* (2015) Metabolic coupling of two small-molecule thiols programs the biosynthesis of lincosmycin A. *Nature* **518**, 115–119.
562. Goldberg A (1959) The enzymic formation of haem by the incorporation of iron into protoporphyrin; importance of ascorbic acid, ergothioneine and glutathione. *Br J Haematol* **5**, 150–157.
563. Anonymous (2019) Clinical trials with mushrooms. <https://clinicaltrials.gov/ct2/results?cond=&term=mushrooms&cntry=&state=&city=&dist=> (accessed January 2020).
564. Cheah IK (2018) Investigating the efficacy of ergothioneine to delay cognitive decline. <https://clinicaltrials.gov/ct2/show/NCT03641404> (accessed August 2019).
565. Gamage AM, Liao C, Cheah IK, *et al.* (2018) The proteobacterial species *Burkholderia pseudomallei* produces ergothioneine, which enhances virulence in mammalian infection. *FASEB J* **2018**, fj201800716.
566. Heath H & Wildy J (1956) Biosynthesis of ergothioneine and histidine by *Claviceps purpurea*. 1. Incorporation of [2-¹⁴C] acetate. *Biochem J* **64**, 612–620.
567. Heath H & Wildy J (1957) Biosynthesis of ergothioneine. *Nature* **179**, 196–197.
568. Pan L, Yu J, Ren D, *et al.* (2019) Metabolomic analysis of significant changes in *Lactobacillus casei* Zhang during culturing to generation 4,000 under conditions of glucose restriction. *J Dairy Sci* **102**, 3851–3867.
569. Pluskal T, Nakamura T, Villar-Briones A, *et al.* (2010) Metabolic profiling of the fission yeast *S. pombe*: quantification of compounds under different temperatures and genetic perturbation. *Mol Biosyst* **6**, 182–198.
570. van der Hoek SA, Darbani B, Zugaj K, *et al.* (2019) Engineering the yeast *Saccharomyces cerevisiae* for the production of L-(+)-ergothioneine. *bioRxiv*, **2019**, 667592.
571. Sotgia S, Zinellu A, Mangoni AA, *et al.* (2014) Clinical and biochemical correlates of serum L-ergothioneine concentrations in community-dwelling middle-aged and older adults. *PLOS ONE* **9**, e84918.
572. Nishigori H, Hayashi R, Lee JW, *et al.* (1984) Effect of MPG on glucocorticoid-induced cataract formation in developing chick embryo. *Invest Ophthalmol Vis Sci* **25**, 1051–1055.
573. Song TY, Yang NC, Chen CL, *et al.* (2017) Protective effects and possible mechanisms of ergothioneine and hispidin against methylglyoxal-induced injuries in rat pheochromocytoma cells. *Oxid Med Cell Longev* **2017**, 4824371.
574. Guijarro MV, Indart A, Aruoma OI, *et al.* (2002) Effects of ergothioneine on diabetic embryopathy in pregnant rats. *Food Chem Toxicol* **40**, 1751–1755.
575. Öztürkler Y, Yildiz S, Güngör O, *et al.* (2010) The effects of L-ergothioneine and L-ascorbic acid on the *in vitro* maturation (IVM) and embryonic development (IVC) of sheep oocytes. *Kafkas Üniversitesi Veteriner Fakültesi Dergisi* **16**, 757–763.
576. Zullo G, Albero G, Neglia G, *et al.* (2016) L-Ergothioneine supplementation during culture improves quality of bovine *in vitro*-produced embryos. *Theriogenology* **85**, 688–697.
577. Moncaster JA, Walsh DT, Gentleman SM, *et al.* (2002) Ergothioneine treatment protects neurons against N-methyl-D-aspartate excitotoxicity in an *in vivo* rat retinal model. *Neurosci Lett* **328**, 55–59.
578. Kawano H, Higuchi F, Mayumi T, *et al.* (1982) Studies on ergothioneine. VII. Some effects on ergothioneine on glycolytic metabolism in red blood cells from rats. *Chem Pharm Bull (Tokyo)* **30**, 2611–2613.
579. Kimura C, Nukina M, Igarashi K, *et al.* (2005) β-Hydroxyergothioneine, a new ergothioneine derivative from the mushroom *Lyophyllum connatum*, and its protective activity against carbon tetrachloride-induced injury in primary culture hepatocytes. *Biosci Biotechnol Biochem* **69**, 357–363.
580. Yoshida S, Shime H, Funami K, *et al.* (2017) The anti-oxidant ergothioneine augments the immunomodulatory function of TLR agonists by direct action on macrophages. *PLOS ONE* **12**, e0169360.
581. Yoshida S, Shime H, Matsumoto M, *et al.* (2019) Anti-oxidative amino acid L-ergothioneine modulates the tumor micro-environment to facilitate adjuvant vaccine immunotherapy. *Front Immunol* **10**, 671.
582. Shinozaki Y, Furuichi K, Toyama T, *et al.* (2017) Impairment of the carnitine/organic cation transporter L-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease. *Kidney Int* **92**, 1356–1369.
583. Menna P, Salvatorelli E, Giampietro R, *et al.* (2002) Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. *Chem Res Toxicol* **15**, 1179–1189.
584. Song TY, Lin HC, Chen CL, *et al.* (2014) Ergothioneine and melatonin attenuate oxidative stress and protect against learning and memory deficits in C57BL/6J mice treated with D-galactose. *Free Radic Res* **48**, 1049–1060.
585. Motohashi N, Mori I, Sugiura Y, *et al.* (1974) Metal complexes of ergothioneine. *Chem Pharmaceut Bull* **22**, 654–657.
586. Motohashi N, Mori I & Sugiura Y (1976) Complexing of copper-ion by ergothioneine. *Chem Pharmaceut Bull* **24**, 2364–2368.
587. Rabenstein DL & Isab AA (1982) A proton nuclear magnetic resonance study of the interaction of mercury with intact human erythrocytes. *Biochim Biophys Acta* **721**, 374–384.
588. Hartman PE & Citardi MJ (1986) Protection afforded by carnosine and by ergothioneine against bacteriophage-P22 inactivation by gamma-irradiation. *Environ Mol Mutagen* **8**, 35–35.
589. Hartman Z, Hartman PE & Owens RA (1986) Ergothioneine (2-thiol-L-histidine betaine = Et) as an antimutagen – interception of direct-acting mutagens formed from nitrosation of spermidine. *Environ Mol Mutagen* **8**, 36–36.
590. Hartman Z & Hartman PE (1987) Interception of some direct-acting mutagens by ergothioneine. *Environ Mol Mutagen* **10**, 3–15.
591. Hartman PE, Hartman Z & Citardi MJ (1988) Ergothioneine, histidine, and two naturally occurring histidine dipeptides as radioprotectors against γ-irradiation inactivation of bacteriophages T4 and P22. *Radiat Res* **114**, 319–330.
592. Ishimoto T, Nakamichi N, Hosotani H, *et al.* (2014) Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons. *PLOS ONE* **9**, e89434.
593. Misiti F, Castagnola M, Zuppi C, *et al.* (2001) Role of ergothioneine on S-nitrosoglutathione catabolism. *Biochem J* **356**, 799–804.



594. Ishimoto T, Masuo Y, Kato Y, *et al.* (2019) Ergothioneine-induced neuronal differentiation is mediated through activation of S6K1 and neurotrophin 4/5-TrkB signaling in murine neural stem cells. *Cell Signal* **53**, 269–280.
595. Chaves NA, Alegria TGP, Dantas LS, *et al.* (2019) Impaired antioxidant capacity causes a disruption of metabolic homeostasis in sickle erythrocytes. *Free Radic Biol Med* **141**, 34–46.
596. Mann T & Leone E (1953) Studies on the metabolism of semen. 8. Ergothioneine as a normal constituent of boar seminal plasma. Purification and crystallization. Site of formation and function. *Biochem J* **53**, 140–148.
597. Williamson RD, McCarthy FP, Manna S, *et al.* (2020) L-(+)-Ergothioneine significantly improves the clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model. *Hypertension* **75**, 561–568.